Podcasts about tirzepatide

Cheaper obesity medicines could unlock broader demand, while supply-chain bottlenecks and premium-drug innovation may also shape how the market evolves. Our analysts Terence Flynn and Thibault Boutherin break down the investor implications.Read more insights from Morgan Stanley.----- Transcript -----Terence Flynn: Welcome to Thoughts on the Market. I'm Terence Flynn, Morgan Stanley's U.S. Pharma and Biotech Analyst. Thibault Boutherin: And I'm Thibault Boutherin, Morgan Stanley's Europe Pharmaceuticals Analyst. Terence Flynn: Today, how cheaper GLP-1 obesity medicines could reshape access, pricing, and supply chains; and what the first generic markets may signal for Europe and the U.S. It's Monday, July 13th at 10am in New York. Thibault Boutherin: And it's 3 pm in London. Terence Flynn: Around one billion people live with obesity worldwide, including over a 100 million in the U.S. Right now, the introduction of the first lower cost generics of semaglutide, a GLP-1 medicine, in some international markets, could have consequences on affordability and demand. Thibault, what are the first countries seeing the introduction of sema generics? What are the current dynamics, and why should global investors pay attention? Thibault Boutherin: Sure. So, so far generics are being introduced this year in three countries: in India, Canada and Brazil. And if we look at India, this is the first market where the generics are being introduced. The patent for semaglutide expired in March 2026, and 13 companies have launched 26 generics across different formulations: autoinjectors, vials, and pills, which price is lower than the branded drug. And because the India market was quite under-penetrated for GLP-1, we are seeing affordability driving volume expansion. In Canada, two generics have been launched so far. Four other generics are waiting for approval, and more are being filed. And finally, in Brazil, one generic was approved last month, and we are expecting these generics to be launched in Brazil in July. And 17 other generics are in different stage of regulatory review in Brazil, and we would expect more to enter the market by the end of this year. And the reason why we focus on these markets is because we believe they could provide a blueprint for what could happen later in the U.S. and in Europe; in particular for Canada, which shares some characteristics with Europe and the U.S. And the patent for semaglutide will expire in Europe in 2031 and in the U.S. from 2032. Terence Flynn: Great. Maybe on the India front, I know that's at the leading edge. What happened with patient demand when price came down? Thibault Boutherin: Sure. So, what we saw in India is a surge in volume when generics were launched, and the volume in April 2026 were already six times higher than the volume in February. And that expansion has been driven mostly by these generics launch, which captured 80 percent of semaglutide volume in April. And our India team expect that the GLP-1 market in India will actually expand in value from $125 million in [20]25 to more than $1 billion by 2030, despite lower prices as we see better, you know, greater volume and greater adoption of GLP-1s in India. Terence Flynn: The other thing, you know, you and I have discussed is the supply chain, and one of the questions is the ability of some of the generic manufacturers to scale semaglutide. So, maybe talk to us about the current capabilities. And could we see bottlenecks in the supply chain formation here? Thibault Boutherin: Yeah, sure. So, there are three key elements to watch on the supply chain. The first is the active pharmaceutical ingredient or API, and that's the semaglutide molecule itself. The second element is the device and the device components, and the third element is the fill and finish, which is basically putting all of these things together. On the API side, so semaglutide molecule, we believe there will be no bottleneck in supplying for generics as we see a handful of large Chinese companies, out of China, building multi-ton capacity for semaglutide. So, we believe there will be no shortage of API to supply the generic supply chain for injectables. On the device, these are the same device companies that are supplying the branded version of semaglutide, and other GLP-1s for the device that are also supplying the generic makers. And we are seeing meaningful investments being made, so we don't believe there will be a bottleneck here. Where we could see a bottleneck emerging is on the fill and finish side. Fill and finish requires highly controlled clean room space to minimize contamination. It requires regulatory approval, and it takes up to three years to build fill and finish capacity. And so, that's where if there is not more investment being made over the next few years, there could potentially [be] a bottleneck emerging for the generic companies. Terence, while semaglutide generics will definitely represent a challenge for the existing branded version of this GLP-1, there are some insights in these emerging dynamics that suggest that tirzepatide, the other GLP-1, could be less at risk. Can you touch a bit on some of these dynamics? Terence Flynn: Absolutely. So, just to remind listeners that semaglutide targets a pathway called GLP-1. Tirzepatide actually targets two pathways. The first is GLP-1, and the second is GIP. And there are some data comparing these molecules, both in Type 2 diabetes and obesity. And tirzepatide gives not only better efficacy but also improved tolerability. And so, what you're seeing in some of the ex-U.S. markets is segmentation, where there are some consumers that are willing to pay a premium price for tirzepatide. Our team in Brazil has done a lot of work on this front looking at this dynamic and, you know, we expect that to play out in many geographies. So, despite the entry of lower-cost generic versions, we think you will still see segmentation of the market between differentiated brand and the lower-cost generics. And that as a result, you will continue to see branded growth.In the U.S. right now, market share is about 60 percent in favor of tirzepatide. And so again, you're seeing a differentiation between these two molecules. Thibault Boutherin: And beyond the introduction of generics GLP-1s, there are other dynamics in the industry that are driving this market. And the introduction of oral drugs this year has been a big topic. Terence, what are your views on the role that orals could play on the market? Terence Flynn: Yes, as a lot of people are probably aware, the many of the existing GLP-1 medicines are injectable. And so those are delivered once a week with a needle. But there are now additional oral options of these GLP-1 medicines. They started off first for Type 2 diabetes, but they have now broadened into obesity as well, following some recent FDA approvals. And what we're seeing is that the introduction in the U.S. so far is expanding the market. So, the majority of people that are taking the oral versions of these medicines are new users to GLP-1s. So again, you're getting market expansion. When you think about the orals as well, one of the other questions is capacity. I know, Thibault, you were talking about the supply chain. There are similar questions for these oral medicines because not all of the oral medicines are the same. Some are easier to manufacture than others, and as a result, that's another variable to consider. So, some of these are what's called peptide-based orals, and some of these are non-peptide-based orals. And the non-peptide-based orals are much easier to scale, for a larger global market. And so that's definitely another variable that we're monitoring and that I think investors need to consider. Thibault Boutherin: And beyond the pill versions of these GLP-1s, we are seeing more innovation in the drug pipeline of the industry, which could be a key driver of differentiation against the competition from the generics. So, what are we seeing emerging today from diabetes and obesity pipelines, which could be exciting for the future of the category? Terence Flynn: So, as we see time and time again in pharmaceutical markets, the key players continue to innovate to try to improve profiles of the existing medications. So, there are, you know, kind of two areas. One would be efficacy; another would be safety tolerability. And so, there are a number of players that are working first to develop longer acting medication. So, as I mentioned, the existing injectable drugs are dosed once weekly. But there are a number of companies that are working to develop potentially monthly or less frequent injections. So, that's one area that we're monitoring closely. And then the second, and again, this plays into what I discussed on tirzepatide, is additional pathways that are involved here in diabetes and obesity, and a number of players are working to target additional pathways beyond GLP-1 and GIP. And so, some of the leading pathways that are being studied are something called amylin and glucagon, and there are a number of medications that are in the late-stage pipeline that are coming along, which have some pretty interesting data. And so that's another area that we're watching. And again, the goal there would be to either improve efficacy and/or improve tolerability versus the existing medications. Thibault Boutherin: Great. And maybe we can also take this opportunity to talk about some of the short-term drivers in the market that are not facing generic today, like the U.S. So, what could be, you know, the key drivers for growth of GLP-1s and the overall obesity and diabetes category over the next five years? Terence Flynn: Yeah, obviously the key one is seeing additional uptake of these medicines. I think right now we estimate, again, obesity in particular, there's about low double-digit percent uptake. And so obviously seeing increasing uptake of these medicines. The orals, as I mentioned, are already driving market expansion. And then the third is access. So obviously in any market, that's very important. In the U.S., I think about 50 percent of employers cover these medications right now. We expect that to increase in the years ahead as the data continues to build. But then this year starting very shortly, the patients in the Medicare program in the U.S., so those people over the age of 65, will be able to access these medicines for $50 per month. And so, we think that is another driver of growth – is this will broaden access to about an additional 18 million people, starting this summer. So, the next phase of the diabesity market comes down to execution, lower cost and scaled supply in the mass market, and innovation and differentiation to compete in the premium segment. Thibault, thanks so much for taking the time to talk. Thibault Boutherin: Great speaking with you, Terence. Terence Flynn: And thanks for listening. If you enjoy Thoughts on the Market, please leave us a review wherever you listen and share the podcast with a friend or colleague today.

Is Ozempic secretly slowing down your thyroid? Millions are using GLP-1 medications like Ozempic for weight loss and blood sugar control, but very few people are being warned about what they could be doing to their thyroid health.If you're experiencing fatigue, hair loss, brain fog, cold hands and feet, constipation, or stubborn weight loss plateaus after starting Ozempic, your thyroid may be sending you warning signs that are often overlooked.In this eye-opening episode of Accelerated Health with Sara Banta, I uncover the surprising connection between Ozempic, GLP-1 medications, and thyroid function, why standard thyroid testing may miss the problem, and the essential nutrients your thyroid needs to function properly.If you're taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication, this is information you don't want to miss.Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care• Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement Not sure what food to eat and avoid? This guide is for you.⬇️

In this episode of Girl Talk with Tay, I sit down with Bracha Banayan, family nurse practitioner, entrepreneur, and founder of IVDrips and Hello Dose, for one of our most fascinating conversations yet. We dive into the science behind GLP-1 medications, why they're about so much more than weight loss, and how they're changing the conversation around longevity, metabolic health, and healthy aging.Bracha explains how GLP-1s work in the body, why weight gain is often rooted in biology rather than willpower, and how factors like glucose, insulin, inflammation, and hormones all play a role in long-term health. We also discuss who may benefit from GLP-1 medications, including women navigating perimenopause and menopause, adults focused on cardiovascular health, and those looking to improve metabolic wellness.We also get into fertility, blood sugar, continuous glucose monitors, and the surprising ways GLP-1s may help reduce cravings by working on the brain's reward system. Beyond medications, Bracha shares the foundational habits she believes everyone should prioritize first from walking after meals and getting morning sunlight to improving sleep and building sustainable wellness routines.Whether you're curious about GLP-1s, trying to better understand metabolic health, or looking for practical ways to optimize your health for the long run, this episode is packed with insights and actionable takeaways.xo, Tay⸻Follow Bracha Banayan!

Send us Fan MailCan We Prevent Muscle Loss While Taking GLP-1 Weight-Loss Drugs?GLP-1 medications like Zepbound have changed the way we treat obesity. But as more people lose significant amounts of weight, another question has emerged:What happens to your muscle?It's normal to lose some lean mass—including muscle—during weight loss. But researchers are now asking whether preserving more muscle could improve long-term health, particularly as we age.In this episode, Dr. Eeks speaks with Dr. Richard Pratley, lead author of a new randomized, double-blind, placebo-controlled clinical trial investigating whether an investigational antibody called apitegromab can help preserve lean mass in people taking tirzepatide (Zepbound).Together they discuss:• Why people lose lean mass during weight loss• What "lean mass" actually means—and why it matters• Why muscle preservation has become one of the biggest new questions in obesity medicine• How apitegromab works by blocking myostatin—a protein that acts like a brake on muscle growth• The results of the study and how much lean mass participants preserved• Why preserving lean mass doesn't automatically mean preserving strength• Whether concerns about muscle loss on GLP-1 medications have become exaggerated• The importance of resistance training and adequate protein during weight loss• Whether future obesity treatment will focus less on body weight and more on body composition• The bigger question: Are we entering an era where one medication leads to another—or is there a better path???This conversation explores one of the most interesting—and practical—questions in obesity research today: Can we lose fat without sacrificing too much muscle?Work with me? Perhaps we are a good match. Keep Causes or Cures Ad-Free with Listener SupportYou can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Follow on X. Or Facebook here.On Youtube.Or TikTok.SUBSCRIBE to her Newsletter here! (the bits not posted on socia media)Support the show

Before EP Description: Learn about the Healing Power of Prolonged Fasting: HEREWhat if losing weight on a GLP-1 drug and losing weight through fasting produce the same number on the scale, but nearly opposite effects inside your cells?Host Dr. Katie Deming believes some of the most popular weight loss drugs on the market may be quietly blocking one of your body's most essential repair processes. Not because they're failing to work, but because they work in a way that keeps your body in a state it was never meant to stay in.She takes an honest, no-shame look at GLP-1 drugs like Ozempic and Wegovy and compares what's actually happening inside your body when you lose weight on them versus when you fast. The scale might show the same number. The story underneath is very different. Dr. Katie explains a repair switch your body can only flip when your stomach is genuinely empty, and why keeping it perpetually fed may keep that switch turned off for good. She connects the dots between mitochondrial health, cellular cleanup, visceral fat, muscle preservation, and metabolic flexibility in a way that's clear, honest, and direct.She's not here to shame anyone taking these medications. She gets why people reach for something that works. But she shares what happened when several of her patients who were certain they'd go right back on the drug after fasting decided they didn't want to, and why.Chapters:00:04:23 - The Food System Is Broken00:06:13 - Your Body Needs Empty Space00:08:24 - GLP-1s May Block Repair Mode00:10:41 - Weight Loss Is Not Healing00:12:26 - What Cancer Cells Feed On00:13:30 - Fasting Changes the Terrain00:17:00 - Cleaning Out Damaged Mitochondria00:18:00 - The Most Dangerous Fat00:20:35 - The Hidden Muscle Loss Problem00:22:20 - Clients Who Were on GLP-1s Before Fasting00:26:06 - Who Should Never Water Fast If you've ever wondered whether weight loss and true healing are actually the same thing, or why one of her patients gained lean mass six weeks after a 14-day water fast, this episode will change how you think about what your body actually needs.Press play and learn why the repair process your body is waiting to run may only start when you finally stop feeding it.Join Dr. Katie's 3-Day Guided Fast, for expert support, daily live calls, and a community to fast alongside: Sign-Up Follow Dr. Katie Deming on InstagramWatch on YoutubeDISCLAIMER: The Born to Heal Podcast  is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.A thought-provoking podcast explores cancer through the lens of holistic medicine and functional medicine, discussing causes of cancer, metabolic health, and unconventional approaches like water fasting, fasting and autophagy, and detox, while weighing fasting benefits against chemo side effects and radiation side effects, sharing stories of a cancer survivor navigating chemotherapy, natural medicine, holistic healing, and even spiritual healing on the path toward cancer remission and holistic health. 

Broadcast from KSQD, Santa Cruz on 7-02-2026: Dr. Dawn devotes the first half of the show to a nuanced defense of GLP-1 receptor agonists, arguing the polarized debate treats obesity as a moral failure rather than a physiological one. She recounts the "Marilyn Monroe dress" moment that transformed semaglutide from diabetes drug into elite cosmetic tool, and pushes back on the puritanical framing that behavior change must be earned rather than pharmacologically enabled—noting we don't apply this logic to antihypertensives or statins. Dr. Dawn catalogs visceral fat as a genuine endocrine organ producing over 17 hormones, most of which drive self-perpetuating growth: leptin (this satiety hormone at high levels disables it's own brain receptor), IL-6, TNF-alpha (blocks insulin), resistin (increases insulin resistance and inflammation), PAI-2 (blocks clot breakdown, raising cardiovascular risk), retinol-binding protein 4 (impairs muscle glucose uptake), chemerin (recruits macrophages and directs fat to the belly), and visfatin. Only adiponectin declines with rising visceral fat. It improves insulin sensitivity, suppresses hepatic gluconeogenesis, and blocks IL-6 . Dr. Dawn describes GLP-1's neurobiological action: receptors in the hypothalamus, brainstem, hippocampus, and mesolimbic reward system, with the drugs quieting the brain's salience network so food loses its intrusive pull. Taste buds shift, sweet and salty become muted, and reward circuits stop firing on cheat foods—creating a window during which behavioral change becomes possible. Dr. Dawn frames group support through self-determination theory (autonomy, competence, relatedness), arguing GLP-1s create the cognitive bandwidth for behavioral programs to succeed. A Tufts study of patients discontinuing after 10% weight loss found those enrolled in behavioral support programs regained about three times less weight than usual-care controls, outperforming even medically-tailored meal plans. Group engagement doubled the time patients stayed on the medication. A November 2025 Nature study piggybacked on deep brain stimulation research at Penn. Electrodes implanted in the nucleus accumbens of post-bariatric patients recorded low-frequency brain activity surges during food-noise episodes on drug free patients. A third participant who started tirzepatide showed complete silencing of that signature—the first direct electrical confirmation that GLP-1s suppresses compulsive food thoughts in the reward center. RNA sequencing of adipose tissue from 25 obese patients before and after bariatric surgery, compared to 24 lean controls, revealed persistent epigenetic changes even after weight loss. Lipid-associated inflammatory macrophages drop but retain some of their pro-inflammatory epigenetics, explaining the well-known slippery slope back to obesity—and why Dr. Dawn suggests GLP-1s may work best as intermittent tools when behavioral maintenance starts slipping. An emailer asks about long-term smoking versus vaping data. Dr. Dawn notes there is no long-term data yet, but short-term evidence shows e-cigarettes contain nicotine, propylene glycol, reactive oxygen species, and nitrosamines, producing spirometry readings similar to mild COPD in otherwise-healthy vapers. Vaping over a year raises stroke relative risk by 1.62 and nearly doubles MI risk, and combining smoking and vaping produces a multiplicative rather than additive harm. Data on cancer will take decades to emerge. Researchers built a functioning underwater breathing apparatus for cockroaches with electrodes attached to brain and sensory organs allowing remote-controlled direction while preserving natural obstacle-navigation autonomy. The 10mm × 10mm sponge-based oxygen tank uses magnesium dioxide catalyzing hydrogen peroxide breakdown, delivering oxygen through silicone tubes to the roach's spiracles for up to three hours underwater. Deployemenet will improve search-and-rescue in flooded and collapsed structures where dogs cannot reach. A Science Advances paper from Yong Lin Kong's lab at Rice University describes 3D-printing electronic circuits directly onto living tissue. Researchers achieved microwave-focused annealing at sub-200-micrometer resolution. By selectively heating only conductive ink particles (copper, silver, gold) without damaging surrounding tissue, the technique enables printing circuits onto 3D-printed heart valves, tracheas, and ear scaffolds, potentially creating combined graft-and-sensor implants, ingestible diagnostic devices, and perhaps even decorative electronic tattoos. A single-shot reformulation of zanamivir (originally the inhaled flu drug Relenza) provided 76.1% flu protection in a 5,000-participant trial—far exceeding the roughly 40-45% offered by annual flu vaccines. Because zanamivir targets neuraminidase in a way that inactivates it if the virus tries to mutate around the drug, trapping newly-made viral copies inside their host cells, this approach works across all flu strains and could bypass the annual guessing game of trivalent vaccine formulation.

It's In the News - a look at the top diabetes headlines and stories happening now. Our top stories: More information about type 1 and COVID, including the vaccine, why is the latest GLP-1 medication, not yet FDA approved, showing up all over the place, what table sugar and vinegar could mean for drug costs, a new inhaled insulin study and much more  I'll see you at Friends for Life next week. Come find me at Table T18 Learn more about our in-person events here: https://diabetes-connections.com/events/ Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Transcript & links:    Okay.. our top story this week: XX A large Swedish study found that the increased risk of being diagnosed with type 1 diabetes after COVID-19 infection is mostly limited to the first 30 days after infection and does not continue long term. Researchers followed nearly the entire Swedish population under age 80 from 2020 through 2023 and found that while SARS-CoV-2 infection was linked to a temporary rise in new type 1 diabetes diagnoses, the risk declined over time. The study also found no evidence that COVID-19 vaccination increases the long-term risk of developing type 1 diabetes. Vaccination did not significantly change the relationship between COVID-19 infection and diabetes risk, and any small increase in diagnoses seen among adults shortly after a first vaccine dose was not seen after later doses or during longer follow-up. The researchers concluded that their findings do not support changing current COVID-19 vaccination recommendations because of concerns about type 1 diabetes risk. https://www.infectiousdiseaseadvisor.com/news/covid19-infection-may-increase-short-term-type-1-diabetes-risk/ XX Two new studies are challenging the traditional view that type 1 diabetes develops solely because the immune system attacks insulin-producing beta cells. Researchers from Indiana University found evidence that beta cells themselves may play an active role in determining whether they survive or succumb to the stresses that lead to type 1 diabetes. In the first study, scientists discovered that some healthy human beta cells can quickly activate an antiviral defense system when exposed to interferon-alpha, an immune signal often produced during viral infections. This response relies on molecules called reactive oxygen species (ROS), which are usually associated with cell damage but, in this case, appeared to help switch on protective antiviral genes. Researchers found this defense program in healthy cells and in people at risk for type 1 diabetes, but not in beta cells from people who already had the disease. The findings suggest that losing this built-in defense mechanism may make beta cells more vulnerable during the development of type 1 diabetes. The second study focused on autophagy, the process cells use to recycle damaged or worn-out components. Using a new imaging technique, researchers observed that beta cells in a mouse model of type 1 diabetes showed defects in autophagy before blood sugar levels began to rise and even before a full immune attack was underway. This suggests that problems inside the beta cells may occur early in the disease process rather than being caused entirely by the immune system. Together, the studies point to a more complex picture of type 1 diabetes. While they do not show that beta-cell defects cause the disease, they suggest that differences in how beta cells respond to stress, viral signals, and cellular damage may influence who develops type 1 diabetes and how the disease progresses. https://medicalxpress.com/news/2026-06-beta-cells-players-diabetes.html XX Researchers have created the most detailed map yet of how the human pancreas develops during childhood, offering new clues about why children are especially vulnerable to developing diabetes. The study, published in Nature Communications, examined pancreatic tissue from 123 children without diabetes, ranging from newborns through age 10. Using advanced imaging techniques, scientists tracked how insulin-producing islet cells grow and mature during the first decade of life. The researchers found that pancreas size varies dramatically at birth, with some infants having pancreases nearly four times larger than others. They also discovered that insulin-producing beta cells grow more slowly after birth than previously thought, suggesting that much of a person's lifelong beta cell capacity may be established before birth and during early childhood. Other findings showed that insulin-producing cells mature earlier than glucagon-producing cells and that new hormone-producing cells may continue to form after birth. The researchers hope this new understanding of pancreas development will help scientists identify diabetes risk earlier and develop better strategies for prevention and treatment in children. https://news.vumc.org/2026/06/29/unlocking-diabetes-secrets-pediatric-organ-donors-help-map-a-path-to-a-cure-and-prevention/   XX At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates of near-normal glycemic control and also led to broader metabolic improvements compared with intensive conventional therapy.   In this MedPage Today video, investigator Stefano Del Prato, MD, of the University of Pisa in Italy, discusses the findings.     Following is a transcript of his remarks:   What happened is that in the tirzepatide-treated arm, 85% of the population at the end of the second year was on the maximum dose of tirzepatide 15 mg. And then the remaining 15 with the different doses.   Interestingly, in the population that had been treated with the intensive conventional approach, 85% of them ended up to have, on top of metformin, a GLP-1 receptor agonist, mainly represented by subcutaneous semaglutide [Ozempic, Wegovy], 60+%, another 15% on oral semaglutide [Rybelsus], and the remaining on dulaglutide [Trulicity].   And I have to say that maybe the recommendation to really push along the line to try to achieve and to strive to achieve [glycemic] control was successful in these individuals. Because the population that had been recruited in the study started off with a baseline A1C of 7.8% and it went down to 6.3% in the conventionally intensive treatment, which is not bad at all, on average is below the target of 6.5%.     However, when we look at the effect of tirzepatide, the final level of A1C at the end of the second year was 5.6%, which is on average below the upper limit of the normal range for A1C, 5.7%. This also translates into more people not only achieving normal glycemia, if we can define normal glycemia as A1C below 5.7%, greater than what we observed in conventionally treated individuals. So it was around three times more people achieving an A1C of 5.7%, in the range of around 65%, as compared to 28% with people on a conventional optimized treatment.   Now, this is not surprising knowing the potency of tirzepatide. But again, going back to the rationale of the design, can we change what is the natural history of the disease? This seems to be at least of interest and it's possibly changing the trajectory of the disease for glycemic control, as I mentioned, but also in terms of the body weight and waist circumference because both body weight and waist circumference went much lower with tirzepatide compared to the conventional treatment.   Tirzepatide also was associated with an improvement in the lipid profile, in particular with the LDL, triglycerides, and the triglyceride concentration and non-HDL cholesterol, and also with a statistically significantly lower systolic blood pressure with a numerical reduction in the diastolic blood pressure.   And also the other thing that probably will ... become more apparent with the study continuing is that the investigators were allowed to add on any other treatment ... needed to achieve their target. So tirzepatide was just metformin and tirzepatide. In the control group, there was already 10% of people who were receiving two drugs on top of the metformin.   So another potential result of the trial is that it's possible to achieve and maintain better glycemic or better metabolic control over the time without really needing to increase the number of medications in order to achieve that goal. And we know that type 2 diabetes is a progressive condition often requiring intensification of the treatment.   So these initial results really stand for a great opportunity with tirzepatide. Of course, we need to wait for the 4 years just to confirm that this is indeed the case, but the initial result seems to point along that line. https://www.medpagetoday.com/meetingcoverage/adavideopearls/121967 XX A study from the University of Virginia found that high blood pressure is extremely common among people with diabetes, even among those who believe their blood pressure is under control. Researchers measured blood pressure in 172 adults with type 1 or type 2 diabetes during routine eye clinic visits and found that only 8% had normal readings. About half had stage 2 hypertension, and more than 10% had blood pressure levels high enough to be considered a medical emergency. The study also revealed that many patients were unaware of how serious their blood pressure problems were. Among those who thought their hypertension was well controlled, more than half still had stage 2 hypertension. Nearly 60% of participants were advised to contact their primary care provider, and one patient required an emergency department referral. Most patients supported blood pressure screening during eye exams, leading researchers to suggest that routine blood pressure checks in ophthalmology clinics could help identify undiagnosed or poorly controlled hypertension before it leads to serious complications such as heart attack, stroke, or worsening diabetic eye disease. https://medicalxpress.com/news/2026-06-routine-eye-exams-reveal-stage.html XX What is going on with retatrutide? This is the next generation GLP-1 but it's not authorized outside of clinical trials. Big investigation by CBS shows retatrutide is for sale all over the internet, a phenomenon they say has no modern precedent. CBS News identified more than 120 websites selling or promoting retatrutide, including more than 50 clinics staffed by licensed medical professionals. After being contacted by CBS News, at least 21 clinics abruptly removed retatrutide from their websites or changed the language to state they don't offer it. Others defended prescribing it, saying they're confident enough in results from clinical trials sponsored by drugmaker Eli Lilly that they didn't need to wait for the FDA's independent, rigorous review. An FDA spokesperson said retatrutide "has not been found safe or effective for any condition," adding that it "cannot be manufactured or distributed except for investigational use." The Justice Department is prosecuting two cases – in Utah and Florida – involving the sale and prescription of retatrutide. But the first line of enforcement is often at the state level. Ohio's Board of Pharmacy has taken action against several pharmacies and clinics providing retatrutide, and just last month, Alabama's Medical Board warned physicians against prescribing research-grade medications. The FDA has sent 14 warning letters to companies that have advertised retatrutide since 2024. Of these, at least six have continued to offer it online, including a business called Pink Pony Peptides. A TikTok account associated with the firm responded to the warning in April by taunting the FDA, boasting that the business "just had the best 24 hours ever." In May, Eli Lilly announced that participants in a large clinical trial taking the highest dose of retatrutide lost an average of 28% of their body weight over 80 weeks. Side effects – including nausea, diarrhea, constipation and vomiting – were comparable to similar therapies, the company said. "Anyone purporting to sell retatrutide to consumers is breaking the law," an Eli Lilly spokesperson said https://www.cbsnews.com/projects/2026/experimental-weight-loss-drug/ XX Pioneering research has developed a new way of creating carbohydrate-based medicines, which could ultimately replace costly drugs for common health conditions, using two cheap basic ingredients – table sugar and vinegar. These medications include SGLT2 inhibitors, widely prescribed drugs used to treat type 2 diabetes, heart failure and chronic kidney disease. Co-lead author Professor Phil Baran, Dr. Richard A. Lerner Endowed Chair at Scripps Research, in San Diego, California, said: "The point of this is to show that anyone in a garage can make an SGLT2 inhibitor with reagents that are widely available. We have not patented this method, so we welcome any generic drug company – or anyone else – who wants to use it to help bring costs down for patients." https://www.newswise.com/articles/new-study-shows-table-sugar-could-hold-a-cheaper-quicker-key-to-making-vital-drugs-for-diabetes-heart-failure-and-chronic-kidney-disease XX England and Wales approve teplizumab to slow progression of T1D. At the moment, the Scottish Medicines Consortium does not have an appraisal of Tzield on the go, so, there is likely to be a disparity in access within the UK for the time being. In Northern Ireland, access will depend on a review and adoption of NICE guidance.  Sanofi is expecting to see an uptick in momentum thanks to two subsequent FDA approvals, one in children as young as one with stage 2 T1D, and a second to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D. btw you might here more people referring to stage 4 diabetes. They've added that to include people diagnosed with type 1 who've been on insulin for a longer period of time – basically long enough to not be eligible for the current guidelines for Tzield. https://www.bbc.com/news/articles/ce8mzd94r76oXX XX Obesity Association, a division of the American Diabetes Association® (the association), announced the next section in the Standards of Care in Overweight and Obesity, "Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults," published in Diabetes, Obesity, and CardioMetabolic CARE® and BMJ Open Diabetes Research & Care.  Key highlights of the guidance: Early screening: Annual BMI screening with emphasis on tracking weight trends to identify risk earlier, including a longitudinal life-event weight graph tool for standardized assessment. Enhanced diagnosis: Combines BMI with waist measurements and population-specific thresholds to improve accuracy. Notably, the guidelines recommend that BMI in the overweight range together with central adiposity measurements warrant a formal obesity diagnosis. Comprehensive evaluation: Holistic assessment including medical, behavioral, and social factors. Offers a fully integrated obesity diagnostic algorithm. Risk stratification: Use of tools like the Edmonton Obesity Staging System to guide care. Chronic care approach: Ongoing monitoring and follow-up to support long-term management. Reducing bias: Promotes person-centered, non-stigmatizing care and system-level improvements at the clinical workflow level and encourages screening for prior weight bias/stigma experiences. https://www.prnewswire.com/news-releases/new-standards-of-care-in-overweight-and-obesity-section-screening-diagnosis-evaluation-and-staging-of-obesity-in-adults-302809670.html XX Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience. San Diego-based Dexcom plans to formally begin the new app rollout in July for Apple iPhone and Android users in the U.S. Dexcom said its reimagined app aims to make glucose insights easier to understand and act on. It hopes to help build awareness of how food, activity, sleep and stress influence overall wellbeing.   The company also reiterated plans to launch Stelo internationally. It expects to bring the sensor to the UK, Australia, New Zealand and South Korea later this year, continuing into 2027. https://www.drugdeliverybusiness.com/dexcom-launches-enhanced-stelo-app/ XX MannKind Corporation recently announced it received a grant from Breakthrough T1D to support the INHALE-1 clinical study of Afrezza, its ultra rapid-acting inhaled insulin, in newly diagnosed pediatric type 1 diabetes patients aged 10 to under 18 years. This external funding for a trial focused on early use of Afrezza in children highlights growing third-party support for inhaled insulin in pediatric diabetes care. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/afrezza-pediatric-trial-grant-might-change-the-case-for-inve XX Alexander Zverev heads into Wimbledon with plenty of momentum. The French Open champion returns to the All England Club looking to build on his first Grand Slam title and gain ground on Carlos Alcaraz in the race for the No. 2 spot in the ATP rankings. Zverev has an opportunity to make up points quickly after a first-round exit at Wimbledon last year. But his final tune-up before Wimbledon came with an unexpected challenge. During his semifinal loss to Taylor Fritz at the Halle Open, Zverev said a malfunctioning glucose sensor led to serious diabetes management issues on court. The sensor incorrectly showed his blood sugar was high when it was actually low, causing him to take more insulin than needed. "I had huge problems with the sugar because the sensor I use gave me a completely incorrect reading," Zverev said after the match. "During the match, or rather during the first 45 minutes, I had to consume about 350 grams of sugar. I felt absolutely terrible." Despite feeling unwell, Zverev pushed the match to three sets before falling 6-7(4), 6-4, 7-5 to Fritz. He credited his opponent with playing the better match and said the diabetes-related issue was not an excuse for the result. Zverev, who was diagnosed with type 1 diabetes at age 4, uses Medtronic diabetes technology to help manage his glucose levels while competing on the ATP Tour. He said the sensor error was the first major problem he has experienced after nearly a decade of using the technology. The German said the incident should not affect his Wimbledon preparations. With the sensor issue behind him, Zverev will begin his Wimbledon campaign focused on adding another strong result to what has already been a breakthrough season.   https://www.reuters.com/sports/tennis/zverev-says-glucose-sensor-malfunction-affected-halle-semi-final-loss-fritz-2026-06-21/

Key Topics CoveredThe Next Frontier in Weight Loss: GLP-1s & Myostatin InhibitorsThe Muscle Loss Problem: While GLP-1 receptor agonists (like Tirzepatide) are highly effective for weight loss, roughly 25% to 30% of the weight lost is actually lean body mass (muscle).The Pharmaceutical Solution: A recent Phase II clinical trial paired a GLP-1 drug with a myostatin inhibitor (which blocks the protein that caps muscle growth), successfully promoting lean mass development while shedding fat.The Practical Alternative: The hosts emphasize that resistance training and adequate protein intake achieve these exact same muscle-preserving results naturally, though large-scale studies on this are rarely funded because "you can't package and sell" exercise.The "Enhanced Games" & Tech-Bro GladiatorsA critique of the upcoming "Enhanced Games"—an Olympic-style event where performance-enhancing drugs are openly allowed.Using baseball's historic steroid era (e.g., Mark McGwire and Sammy Sosa) as an example, they discuss how performance enhancers amplify raw power margins without actually replacing foundational athletic coordination.A humorous look at the logical extreme of this trend: transitioning from myostatin inhibitors to full-blown CRISPR genetic engineering, drawing parallels to the movie Gattaca.The Rise of "Wellness Burnout"Wellness Maxing: The multi-billion-dollar wellness industry has created a exhausting "firehose" of protocols, leaving people overwhelmed by red-light masks, cold plunges, complex morning supplement "stacks," and hyper-optimized mattress coolers.The Power of Subtraction: The hosts advocate for simplifying your health routine rather than adding to it. They recommend automating simple meal choices, hitting a baseline of 20 minutes of daily exercise, and finding community-based, accountable activities like pickleball to naturally reduce stress and fight social isolation.

Check Out BioVitalis Peptides: https://biovitalis.org/ (Use Promo Code: GSD10 for 10% off)   Check Out Jim Brown's Substack Blog: https://substack.com/@forj   *Disclaimer: This NOT medical advice. Please make sure to seek your own medical professional for medical advice.

0:00- Intro1:00- Tirzepatide 5:00- Using tirzepatide vs strict discipline14:00- Accurately tracking calories23:45- Differences in metabolism vs appetite 30:00- Potential consequences of being very lean34:00- Incorporating refeeds 35:00- Being shredded42:00- Using medications48:30- Why not retatrutide?51:15- How is strength while this lean?55:00- Realities of later natural lifting1:03:45- Kinoclinic Website and Coaching: https://brainsandgainspodcast.com/Instagram: https://www.instagram.com/dave_maconi/David Protein Link: https://davidprotein.com/BAGCode: BAGhttps://www.youtube.com/channel/UCW-PI9YMJ6SXPiqXy2FYfLg/join-For those looking to support the channel and our donations to various charities, please consider the above link to become a member and have the opportunity to appear on the channel!

In this podcast, Jennifer Green, MD, and Jay H. Shubrook, DO, FAAFP, FACOFP, share strategies for integrating incretin-based therapies in type 2 diabetes (T2D) management in the primary care setting, including: Importance of moving beyond a glucose-centric approach to T2D care  Current evidence for incretin-based therapies in T2D Rationale for integrating these therapies into the primary care setting Shared decision-making strategies to discuss optimal T2D treatment options with patients Timing for endocrinology referral Presenters: Jennifer Green, MD Professor of Medicine Division of Endocrinology Duke Clinical Research Institute Duke University School of Medicine Durham, North Carolina Jay H. Shubrook, DO, FAAFP, FACOFP Professor, Diabetologist Department of Clinical Sciences and Community Medicine Touro University California, College of Osteopathic Medicine Vallejo, California Full program link: https://bit.ly/4uSKCqv Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into the latest scientific breakthroughs, regulatory advancements, and strategic industry movements that are shaping the landscape of healthcare innovation. Kicking off with significant strides in drug approvals, Carsgen Therapeutics has marked a major milestone with the approval of satricabtagene autoleucel by China's National Medical Products Administration. This cell therapy is designed to target Claudin18.2-positive advanced gastric and gastroesophageal junction adenocarcinoma, a notoriously tough solid tumor. The approval follows successful Phase 2 trials, underscoring progress in targeted cancer therapies—a field particularly crucial for gastric cancers due to their heterogeneous nature. Meanwhile, Sanofi's Cenrifki (tolebrutinib) has gained approval in the EU for secondary progressive multiple sclerosis treatment. As a small molecule BTK inhibitor, it demonstrated efficacy during Phase 3 trials, providing a new avenue for managing progressive neurological disorders. This approval marks an important addition to therapeutic options for conditions with historically limited treatments. In parallel developments reflecting the shift towards precision medicine, Pierre Fabre's Braftovi (encorafenib) received European Commission approval as a first-line treatment for BRAF V600E-mutant metastatic colorectal cancer. Similarly, Gilead Sciences' Trodelvy (sacituzumab govitecan) has been approved as a first-line treatment for unresectable or metastatic triple-negative breast cancer in the EU, highlighting the expanding role of antibody-drug conjugates in oncology. AbbVie's Skyrizi (risankizumab) also gained European endorsement for pediatric use in moderate to severe plaque psoriasis. As an IL-23 inhibitor monoclonal antibody, Skyrizi exemplifies the growing trend of biologics targeting autoimmune conditions with high specificity and efficacy. On the regulatory front, the U.S. Department of Health and Human Services and FDA have launched an unprecedented initiative to reduce clinical trial timelines. This reform aims at reinforcing U.S. leadership in drug development by addressing operational efficiencies crucial for accelerating new therapies' availability, especially in oncology and rare diseases. Efforts to expedite Phase 1 clinical trials by up to 12 months are underway by federal health agencies aiming to enhance U.S. competitiveness against China's burgeoning clinical development capabilities. Economic forecasts are predicting that Eli Lilly's tirzepatide will lead a surge in global drug sales driven by obesity treatments, potentially reaching $2 trillion by 2032. As a GLP-1 receptor agonist, tirzepatide's success underscores the growing emphasis on metabolic disorders as major therapeutic targets due to their widespread prevalence and impact on public health. Strategic partnerships continue to shape the industry landscape. Merck KGaA and Versant Ventures have launched Saturnus Bio with a $50 million investment aimed at advancing therapies for rare genetic heart diseases. In another instance of strategic collaboration, Bayer is working with Iambic Therapeutics to leverage AI-driven discovery for challenging small-molecule targets, reflecting an increasing reliance on artificial intelligence to overcome traditional drug discovery hurdles. In clinical trials, Corxel Pharmaceuticals' CX11 met primary endpoints in Phase 2 studies for obesity, showcasing promising weight loss results with an oral GLP-1 small molecule. This advancement could potentially offer more accessible treatment options compared to injectable formulations. However, challenges persist as seen with Sangamo's bankruptcy filing amidst acquisition interest from Eli Lilly and Astellas, highlighting financial vulnerabilities even among pioneering gene therapy entities. Additionally, setbacks in pivotal trials like Exelixis' Zanzalintinib missing its colorectal cancer endpoint illustrate the high-risk nature of oncology drug development despite anticipated FDA approval. Across the sector, Pfizer's acquisition of Seagen faced hurdles when their antibody-drug conjugate sigvotatug vedotin failed in a Phase 3 trial for non-small cell lung cancer. This setback highlights risks inherent in biopharmaceutical investments and innovations. As these developments unfold, they reflect a dynamic industry driven by scientific innovation, strategic collaborations, and regulatory shifts aimed at enhancing patient care through more effective and tailored therapies. The increasing integration of technology such as AI in drug discovery further underscores the evolving landscape of pharmaceutical R&D toward precision medicine and operational efficiency. Today's insights not only signify groundbreaking scientific advances but also illustrate how companies adapt to regulatory environments and market opportunities—all critical elements that will shape the future direction of global healthcare delivery. Stay tuned for more updates as we continue exploring these transformative changes across the pharmaceutical and biotech industries on Pharma Daily.Support the show

Ti promettono meno fame.Ti promettono una perdita di peso rapida.Ti promettono una soluzione che fino a pochi anni fa sembrava impossibile.E per molti versi mantengono la promessa.Ozempic, Wegovy, Mounjaro e i nuovi farmaci per il dimagrimento stanno cambiando il modo in cui milioni di persone affrontano il problema del peso.La bilancia scende, l'appetito si riduce e per la prima volta molte persone riescono a ottenere risultati che sembravano irraggiungibili.Ma c'è una domanda che quasi nessuno si pone.Qual è il conto da pagare?Perché ogni volta che una soluzione sembra troppo semplice, vale la pena fermarsi un attimo e guardare cosa succede dietro le quinte.In questo episodio del podcast Vivere in Chetogenica, il Dott. Lorenzo Vieri affronta il lato meno raccontato dei farmaci GLP-1 come Ozempic, Wegovy e Mounjaro.Non per demonizzarli. Non per creare paura. Ma per riportare equilibrio in una conversazione che spesso racconta solo una parte della storia.Parleremo degli effetti collaterali gastrointestinali che molte persone sperimentano, della nausea, della stitichezza, delle difficoltà digestive e della gestione dell'alimentazione durante il trattamento.Ma soprattutto parleremo di ciò che rischia di diventare il vero problema dei prossimi anni: la perdita di massa muscolare.Perché perdere peso non significa automaticamente migliorare la propria salute.Se il peso perso arriva in parte dai muscoli, il metabolismo ne paga il prezzo.E quel prezzo può manifestarsi proprio nel momento in cui il farmaco viene sospeso.Affronteremo inoltre il tema del costo economico, della difficoltà di interrompere queste terapie, del rischio di recuperare il peso perso e di una verità che spesso viene dimenticata: nessuna puntura può sostituire un cambiamento reale delle abitudini.Il farmaco può essere uno strumento.Ma non può diventare il progetto.E se durante il percorso non costruisci nuove competenze, nuove abitudini e un nuovo rapporto con il cibo, il rischio è quello di ritrovarti esattamente dove eri partito.Con qualche chilo in meno oggi.E molti più problemi domani.

A few years ago, I came across a quote that said:"I think the key to a happy life as an adult woman is to channel your inner weird little girl and make her happy."It immediately resonated with me.I was the kid making potions in the yard, obsessed with magic books, fortune tellers, mood rings, crystals, and all things mystical. And the older I get, the more I realize those parts of me never disappeared—they just got buried under adulthood and responsibility.In this episode, I'm talking about whimsy—not as a trend, but as a way of reconnecting with yourself. I'm sharing what's on my whimsical summer list, why I've been intentionally making more room for wonder, and how this connects to one of the core principles of Irresistible You: Feed Your Soul.Because maybe creating a magical life isn't about becoming someone new.Maybe it's about remembering who you've been all along. ✨

Semaglutide. Tirzepatide. Retatrutide. The peptide conversation has taken over every gym, group chat, and social media feed. But the part about muscle loss, osteopenia, and what the gray market is actually selling you? That part is getting buried. Chalene Johnson sits down with Adam Schafer, co-host of Mind Pump, one of the top fitness podcasts in the world with nearly half a billion downloads. Adam spent three and a half years running real test groups on GLP-1s including Ozempic and Wegovy. What he found changed his perspective entirely and he is not holding back. This conversation covers what is actually driving muscle and bone density loss in women over 40 and 50, why the scale and the mirror are lying about body composition, and what most women are getting wrong about building real strength in midlife. Plus the truth about the gray market and what those peptides may actually contain. This is the conversation the fitness industry is not having and it is one every woman over 40 needs to hear.

In part two of the GLP-1 series, Melissa gets practical. What does it actually feel like to be on this medication? What does responsible use look like day to day? And how do you get the best results at the lowest effective dose possible?Whether you just started, you're a few months in, or you're wondering why you're not seeing the results you expected — this episode is for you.IN THIS EPISODE, YOU'LL LEARN:Why you forget about food on a GLP-1 and why that feeling of relief is also where your responsibility beginsWhat the flat affect actually is, why it happens, and what it tells you about your doseWhy GLP-1 receptors live in the brain's reward center — and what that means for your dopamine, your drive, and your nervous systemThe difference between microdosing and the lowest effective dose (and why that distinction matters more than the label)FDA-approved dosing for semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — and where Melissa would actually startWhy digestion has to come first before or while on this medicationThe truth about blood sugar stability on a GLP-1 and why the medication doesn't do that work for youWhy women on GLP-1 are losing muscle without realizing it — and exactly what to do about itProgressive overload: what it actually means and why going through the motions isn't enoughWhy Melissa recommends Cronometer over MyFitnessPal for tracking on a GLP-1Hair loss — medication side effect or weight loss side effect? Melissa breaks down the differenceFatigue — why it's actually both, and what to do depending on which one it isWhy perimenopause symptoms can get louder on a GLP-1 and what's happening hormonallyHow to know if you're actually at a plateau (hint: four weeks is the threshold)What to do when you're at max dose and the scale still isn't movingHow long is it okay to stay on a GLP-1 — and what the long-term concerns actually areTIMESTAMPS:00:00 — Welcome back + recap of episode one 01:45 — What it actually feels like when you first start 03:30 — The flat affect and the dopamine loop 07:50 — Strength training as a natural dopamine regulator 10:00 — The lowest effective dose and what microdosing actually means 12:00 — Semaglutide dosing overview (Wegovy, Ozempic) 13:45 — Tirzepatide dosing overview (Zepbound, Mounjaro) 15:00 — How to advocate for a lower starting dose with your provider 16:00 — Melissa's personal experience: 1 mg tirzepatide for inflammation 23:30 — Making the medication work hard for you: the foundation 25:00 — Digestion first — why gut health matters before you start 26:30 — Blood sugar stability is your responsibility 29:00 — Protein first, always 31:00 — Why women on GLP-1 are losing muscle 33:30 — Progressive overload — what it actually looks like 35:00 — Track your food — why Cronometer and why it's non-negotiable 38:30 — Side effects: medication vs. weight loss (two different categories) 39:00 — Hair loss explained 40:50 — Fatigue explained 42:00 — Nausea, constipation, gut symptoms 42:45 — Perimenopause, hormonal shifts, estrogen dominance44:30 — How to know if you're actually at a plateau 48:00 — Max dose: what to do when you're there 48:30 — How long is it okay to stay on a GLP-51:00 — Download the GLP-1 Support Guide + closeRESOURCES:Download the GLP-1 Support Guide — everything you need to use this medication responsibly: workouts with logging space, protein meal plan, nutrition framework, and tracking tools. melissaeichwellness.com/GLP1guideBook a free consultation with Melissa — whether you're considering GLP-1, already on it, or wanting gut or hormone support while on it: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=6a0cb936104f4243883a46dfGut Healing Program or Complete Hormone Program: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=69fe864f4b36932a1ec4aba4Related episodes:Episode [#179]: GLP-1 Series, Part 1 — The Shame, the Gray Area, and Weight Loss Resistance: https://podcasts.apple.com/us/podcast/179-glp-1-for-midlife-women-where-to-begin-part-1-3/id1650475536?i=1000771142749DUTCH test series — perimenopause, weight loss resistance, and estrogen detox - https://podcasts.apple.com/us/podcast/176-perimenopause-weight-gain-and-the-dutch-test/id1650475536?i=1000767363294CONNECT WITH MELISSA:Instagram: @melissa_eich Website: melissaeichwellness.com Email: melissa@melissaeichwellness.comABOUT THE SHOW:Body-Led by Design is a podcast for women who are done guessing and ready to understand what's actually happening in their bodies. Hosted by Melissa Eich, registered nurse, hormone and nervous system coach, and somatic practitioner, each episode brings the real conversations from her practice so you can walk away more informed, more empowered, and a little less alone in what you're navigating.LEAVE A REVIEW:If this episode resonated with you, a five-star review means the world. It helps more women find this podcast and get the information they actually need.SEO KEYWORDS:GLP-1 side effects, semaglutide weight loss, tirzepatide lowest effective dose, microdosing GLP-1, hair loss on Ozempic, muscle loss GLP-1, weight loss plateau GLP-1, GLP-1 fatigue, Wegovy responsible use, perimenopause GLP-1, how long to stay on GLP-1, GLP-1 support women over 40

GLP-1 stopped working? Or is your body trying to tell you something deeper?In this episode, Kylie unpacks the REAL reason so many women hit a weight loss plateau while taking Ozempic, Mounjaro, Semaglutide or Tirzepatide… and why the answer is NOT always “eat less” or “increase your dose.”You'll learn: • Why GLP-1 plateaus happen • The hidden danger of losing muscle while dieting • How chronic stress and cortisol can stall fat loss • Why blood sugar regulation matters more than calories alone • The truth about “metabolic damage” • How under-eating protein can slow your progress • Why your nervous system affects the scale more than you think • The biggest mistakes women make when their appetite drops • How to support your metabolism WITHOUT spirallingThis episode is a must-listen for women over 40 who feel frustrated, stuck, inflamed, exhausted, or scared that their body has “stopped responding.”Because your body isn't broken, babe. It's adapting.And once you understand what's really happening beneath the surface… everything changes.

Calum Raistrick, Niall Darwin (onepunchnaz)APR Health Solutions Peptides: www.aprhealthsolutions.com - code nyleOptimize HRT Clinic: https://members.optimize-hp.com - code nyleMerch: https://www.aykons.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'nyle' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘nyle' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comRP Hypertrophy Training App: rpstrength.com/nyle (code nyle)0:00:00 - Intro0:02:04 - University Days & Naive PED Use0:05:03 - Gut Health & The 1.5g Protein Limit0:10:05 - Midsection Vacuum & Classic Weight Caps0:16:24 - The Real Cause of Waist Growth0:19:34 - Total Drug Load vs. Visceral Fat0:22:30 - Conditioning Secrets: Classic vs. Open0:28:28 - Niall's 12-Week Pittsburgh Prep Plan0:32:47 - Compound Tapering & Injection Risks0:35:02 - Extreme Prep Protocols: Martin & Boss0:40:57 - Systemic Stress & "Landing the Plane"0:43:12 - Blowing a Load the Night Before Show0:43:34 - John Meadows' "Grainy Skin" Secrets0:45:45 - Linear Peaking vs. Volatile Refeed Gauging0:48:45 - Strategic Atrophy & Leg Volume Slashes0:50:15 - Quad & Glute Volume Tiers0:52:08 - Tyler Smith's Extreme Leg Volume Slash0:53:19 - Peptide Protocols & Organ Protection0:55:21 - The Elite Client Portfolio0:57:11 - Coaching Content Creator Brandon Harding1:00:03 - Influencer Stress & Off-Season Fat Fear1:01:37 - Off-Season Fat Anxiety1:02:06 - What Makes a Coach Most Anxious?1:04:16 - Bodybuilding Page Tags & Lineups1:05:00 - Analyzing Kyron Holden & Ryan Terry1:06:47 - Managing Cortisol, Stimulants & Sleep1:11:46 - Advanced Peptides: SLU-332 & GC-11:12:44 - T3 Abuse vs. T4 & Sobetirome Replacement1:13:33 - GLP-1 Downsides in Contest Prep1:14:25 - Tirzepatide for Post-Show Reverse Phases1:16:05 - Why GLP-1s Ruin Peak Week1:20:36 - Compounding vs. Research Chemicals1:21:21 - Blood Panels & Wellness Specialists1:23:16 - GH & Insulin in Classic Physique1:24:46 - Insulin Dosing as an Off-Season Support1:25:24 - Nighttime GH Bolus vs. Microdosing1:27:00 - Patrick Tuor's Insulin-GH Synergy Theories1:28:55 - Lantus vs. Rapid-Acting Insulin Placement1:30:40 - Working with Niall Darwen1:31:29 - Height Measurements and Weight Caps1:32:44 - Height Manipulation & Spinal Decompression1:35:03 - Niall's Future Back Density Strategy1:36:26 - Pittsburgh Pro Post-Weigh-In Load1:37:37 - Off-Season Fiber & Gut Linings1:39:19 - Oral Steroid Toxicity & Digestion Dampening1:40:41 - Low-Dose Oral Strategies1:42:06 - 100mg Winstrol Motility Shutdown1:46:09 - Post-Show Recovery Phase vs. Rebound1:48:09 - Systemic Muscle Memory & Cell Sensitivity1:49:05 - Scientific Training Philosophy1:50:53 - Zachariah's 34kg Hypertrophy Miracle1:52:24 - Slow Eccentrics & Mind-Muscle Intent1:54:40 - Hyper-Focus During Sets1:56:53 - Comprehensive Blood Work Markers1:57:58 - Cruising Protocol Adjustments2:00:15 - Dietary Fats with Pre-Workout Insulin2:01:32 - Coaching Dynamics of Close Friends2:05:00 - Eric's Open Division Transition2:06:10 - Regional Coaching: UK Intensity vs. US Volume2:06:36 - Laszlo Karoly's Density & US Shows Strategy2:07:29 - Slow-Twitch vs. Fast-Twitch Muscle Genetics2:12:01 - Building Exceptional Muscle Mass2:14:20 - One Final Message: Back Yourself First

What if the newest “miracle” weight loss prescription is hiding the SAME root problem as Ozempic?Retatrutide is being called the next-generation fat loss breakthrough… promising even MORE dramatic results than Ozempic. But before you jump on the hype, there's something no one is talking about.Could rapid weight loss come at the expense of your metabolism, muscle mass, hormones, and long-term health?Watch until the end before deciding if Retatrutide is really “better.” Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement  • Accelerated Methylene Blue® https://www.acceleratedhealthproducts.com/products/accelerated-methylene-blue-supplement • Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement • Accelerated Fast® https://www.acceleratedhealthproducts.com/products/accelerated-fast-supplement • Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care• Accelerated Cellular Detox® Powder https://www.acceleratedhealthproducts.com/products/accelerated-cellular-detox-powderNot sure what food to eat and avoid? This guide is for you.⬇️

In this episode, I'm talking honestly about weight loss burnout. The mental exhaustion that comes from constantly thinking about food, planning meals, trying to “be good,” starting over, tracking, and feeling like your body is always a project that needs fixing.I also share what this experience has been like for me while being on Tirzepatide. The food noise is quieter, but now I find myself in this strange in-between space where I'm hungry, but nothing sounds good. I take a few bites and feel full… while somehow still feeling hungry at the same time. And honestly? I'm tired.This episode isn't anti-weight loss. It's about what happens when your entire life starts revolving around shrinking yourself, and the realization that maybe peace matters too.Because you deserve a life bigger than calorie counting.Show Notes

Hi, it's Heather and I'm so glad you're here! Welcome to the newly renamed Health, Harmony and Heather podcast! This space is dedicated to exploring social phenomena, the human condition, and how we can better connect with ourselves, each other, and the planet. In this episode, I'm thrilled to welcome back my personal clinician and friend, Lauren Rosenberg. Lauren is a highly experienced physician associate, internal medicine expert, and the founder of Vent Health, a practice dedicated to shifting the medical focus from disease treatment to true preventative care and health optimization. Today, we are stripping away the stigma and diving deep into the raw science, truth, and real solutions for perimenopause, menopause, and post-menopause. The days of women suffering in silence are over. The "One Day" Truth: Why menopause is actually just one single day in your life, and what it means for your timeline. The Hormone Rollercoaster: A breakdown of how estrogen, progesterone, and testosterone behave during your cycle—and what happens when they plummet. Symptoms Beyond Hot Flashes: From brain fog, joint pain, and "frozen shoulder" to anxiety, weight gain, and urinary changes. The WHI Study Debunked: The real story behind the 2002 Women's Health Initiative study that scared a generation away from life-saving hormone replacement therapy (HRT). The Power of Peptides: How cutting-edge tools like GLP-1s, Tirzepatide, Retatrutide, and cellular repair peptides can be paired with HRT for total vitality. At-Home Longevity Habits: The non-negotiable lifestyle habits—including grip strength, Zone 2 training, lifting weights, protein intake, and specific magnesium variations—to help you thrive. Connect with Lauren Rosenberg: Learn more at myventhealth.com or follow her on Instagram @MyVentHealth. Virtual Menopause Care: Check out Midi Health (joinmidi.com) for accessible, insurance-based virtual menopause care. Trusted Supplement Brands: Designs for Health, Pure Encapsulations, Thorne, and Metagenics. AirDoctor.  Head to www.AirDoctorPro.com  and use promo code HEATHER to get $250 off select AirDoctor air purifiers, including the 3500, 4000, and 5500 models. Plus, you'll receive a free 3 year warranty, an $84 value, and AirDoctor's 30-day money back guarantee. This is an exclusive podcast only offer, available now! Don't forget to LIKE this video, SUBSCRIBE to the channel, and hit the notification bell so you never miss an episode. Let's live the last third of our lives with vitality, strength, and harmony! #Menopause #Perimenopause #HormoneReplacementTherapy #HealthyAging #Peptides #Longevity #WomensHealth #HealthHarmonyAndHeather Learn more about your ad choices. Visit megaphone.fm/adchoices

In this solo episode of Mommywood, I'm opening up about my personal experience taking tirzepatide after struggling with postpartum weight, brain fog, exhaustion, and constant “food noise” after having my daughter. I talk about what finally pushed me to try it, how it affected my relationship with food, my confidence, energy levels, and even the way I approach self-tapes as an actor mom.I'm also sharing the questions I wrestled with around body image, motherhood, stigma, and whether it felt like “cheating.” Plus, I answer listener questions about side effects, costs, microdosing, acting, parenting, and what happens after stopping.This episode is not medical advice — it's simply me honestly sharing my own experience navigating wellness, identity, and confidence in motherhood and Hollywood.

Welcome to the latest episode (June 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Update: Shah S, et al. "Food Coloring Additives and Incidence of Type 2 Diabetes in the NutriNet-Santé Prospective Cohort Diabetes Care. 2026;49(6):1067–1077. doi.org/10.2337/dc25-2727 Hespanhol L, et al. "Automated Insulin Delivery Systems in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis." Diabetes Care. 2026;49(6):1134–1143. doi.org/10.2337/dc25-2435 Tatum K, et al. "Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer." JAMA. Published Online: May 11, 2026 2026;9;(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133 Winkler C, et al. "Screening Children for Early-Stage Type 1 Diabetes." JAMA. Published Online: May 21, 2026 doi:10.1001/jama.2026.6085 Würtz Yazdanfard P, Kosjerina V, Wood-Kurland H et al. "Effectiveness and Safety of Semaglutide in Type 1 Diabetes: A Danish Nationwide Cohort Study (2018–2024)" Lancet. Volume 66, 101716, July 2026. doi:10.1016/j.lanepe.2026.101716 Horn D, Aronne L, Wharton S et al. "Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial." Lancet. Published online May 12, 2026. doi:10.1016/S0140-6736(26)00656-2 Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here.

Taylor and I are back for another Reader Mailbag. This one covers a lot of ground.We start with anhedonia on GLP-1s because the questions on this have been nonstop. People are experiencing it on Semaglutide, Tirzepatide, and Retatrutide and we break down why it happens, whether it is dose related, and what you can actually do about it.From there we get into the Reta and heart rate debate, Taylor's GLP rotation strategy, and whether the cardiovascular tradeoffs are actually worth worrying about.Then Taylor takes over for the hormone optimization section for young women in their twenties and thirties. Her personal story on this one is worth watching alone.We also cover accidental peptide overdoses, what to do when it happens, and finish with teen acne solutions using peptides and topicals.Submit your questions for the next episode at the link below.For research and entertainment purposes only.Links, cheatsheet, private group and more

In this episode, we break down the science behind GLP-1 medications including Ozempic, Wegovy, Zepbound, Mounjaro, semaglutide, and tirzepatide. Learn how GLP-1 weight loss medications work, their role in appetite suppression, insulin regulation, metabolic health, obesity treatment, and type 2 diabetes management.This evidence-based discussion explores GLP-1 benefits, side effects, muscle loss concerns, weight regain after stopping medication, nutrition considerations, digestion, metabolic adaptation, and sustainable wellness strategies. If you're considering GLP-1 medications or simply want a smarter conversation about obesity medicine, weight loss, longevity, and metabolic health, this episode delivers a clinically grounded wellness perspective. Disclaimer: This podcast is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The views shared are intended to support informed wellness conversations and should not replace individualized guidance from your physician or qualified healthcare provider. Always consult your healthcare team before making decisions regarding medications, treatment, nutrition, or health management.

Tirzepatide, marketed as Zepbound, mimics the action of GLP-1 and GIP, two hormones naturally released by your gut. These hormones are critical in regulating appetite and how much food you consume. By enhancing the feeling of fullness and reducing hunger, tirzepatide helps support weight loss. Read the Full Episode Transcript: https://pepties.com/common-questions-of-tirzepatide/ Related Links/Products Mentioned: Peptide Podcast Partners Page https://pepties.com/partners/ Buy Peptides online at BioLongevity Labs: Use our link and enter COUPON CODE: PEPTIDEPODCAST  at checkout to receive 15% off your total order:  https://go.biolongevitylabs.com/SH5C Momentous Supplements (we use Creatine, Vital Aminos, Whey Protein) https://crrnt.app/MOME/OqGQOxGA LMNT – More Salt, Not Less.  https://elementallabs.refr.cc/default/u/johnjavit Thorne Supplements (we use Omega-3 with CoQ10, Red Yeast Rice, Zinc) https://get.aspr.app/SH1KvW Organifi Creatine and Shilajit Gummies http://rwrd.io/rlbkajm?c MitoZen (methylene blue for Cognitive Function, Anti-Aging, Mental Clarity) https://www.mitozen.com/ref/cnlwiztypt/ For skin and hair health (Copper Tripeptide-1)  Visit Luminose by Entera for an exclusive offer for Peptide Podcast listeners!  ** Promo code PEPTIDEPODCAST at checkout for 10% off an order or 10% off the first month of a subscribe-and-save. ** https://www.enteraskincare.com/?rfsn=8906839.f93c72 NAD+ Push Patch: https://www.pushpatch.com/

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Orforglipron for maintenance of body weight reduction  - Nature Medicine2026. Discussion by:Guest:Joe Gonella, MD Resident - Abington Family Medicine Residency Program Jefferson Health2. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN) Lancet 2026.  Discussion by: Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney  Kimmel  Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington3. Survival and Recurrence with GLP-1 Receptor Agonists in Breast Cancer" – JAMA Network Open Discussion by:Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney  Kimmel  Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington4. In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.   NEJM 2026 Discussion by:Guest:Alex Sauer, MD Resident - Abington Family Medicine Residency ProgramJefferson HealthMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

All links here: ⁠https://hunterwilliamshealth.com/linksTimestamps:00:00 Intro01:00 Why I'm making this video04:00 The plan: peptides with direct anti-cancer evidence06:02 AOD-9604 and HGH Frag 176-19107:42 BPC-15709:54 DSIP (Delta Sleep Inducing Peptide)11:08 Epitalon12:30 Follistatin 34413:30 GHK-Cu14:36 Kisspeptin15:58 KPV17:18 LL-3718:46 Melanotan 219:58 MOTS-c21:12 Retatrutide22:34 Semaglutide23:40 SS-3124:38 Thymalin25:26 Thymosin Alpha-127:00 Tirzepatide27:30 VIP (Vasoactive Intestinal Peptide)28:06 Bottom line and closing thoughtsDescriptionIf you spend any time in the peptide social media world, you've heard it. "Peptides cause cancer." It's the easiest way to scare someone off something, and a lot of people do it without ever showing you a single study.So I went and pulled the studies. In this video I walk through every peptide on the popular research peptide list that actually has direct anti-cancer evidence in the published literature. Not theory. Not mechanism guesses. Actual studies in cells, animals, and in some cases, humans.You'll see what the research says about BPC-157, GHK-Cu, Epitalon, KPV, LL-37, Thymosin Alpha-1, MOTS-c, semaglutide, tirzepatide, retatrutide, and a handful more. Some of this evidence is strong. Some is preliminary. I'm honest about both.This is not medical advice and I'm not telling you peptides cure cancer. That's not what the data says and that's not what I'm claiming. What I am saying is that the next time someone hits you with a 60 second clip telling you peptides cause cancer, you'll have something more substantial to weigh it against.All study links below.

Free Energy Balance Food Guide: https://jayfeldmanwellness.com/guide 
The Nutrition Blueprint: https://mikefave.com/the-nutrition-blueprint/ 
Theresa's Instagram: https://www.instagram.com/livingrootswellness/   
Timestamps: 0:00 – intro  1:32 – Mike Israetel on Retatrutide as the next “miracle drug”  4:06 – concerns with increasing glucagon: thyroid, fat metabolism, reproductive hormones  7:22 – Retatrutide leads to more aggressive weight loss at the expense of health  10:17 – is Retatrutide really healthier for your internal organs (fatty liver, heart, kidney)  11:41 – healthy weight loss does NOT have to be uncomfortable  14:44 – Retatrutide signaling explained: what are the long-term effects?  20:46 – extreme dieting feels terrible for a reason; restriction is not the solution  24:10 –Mike Israetel's diet explains his view of Retatrutide  27:50 – Kinobody (Greg O'Gallagher) says using GLP-1 medications is “high IQ"  31:29 – are GLP-1s just a “modern day tool” without consequences?  33:22 – is constant food availability the reason for widespread weight gain and obesity?  40:24 – why Greg Gallagher is getting push-back for taking Tirzepatide  43:09 – does “food noise” justify GLP-1s?45:20 – many fitness influencers have body image issues and perpetuate the cycle  50:40 – the truth about being lean/ripped – what's actually healthy?  57:57 – obsession with body composition as a sign of poor health  1:02:03 – success story: from low-carb fear to feeling better with carbs  1:04:40 – why people are afraid to try carbs again after low-carb and common mistakes people make when reintroducing carbs   

Dr. Ksenia Petrushkina joins Dr. Mike Hart for a deep dive into regenerative medicine, peptides, hormones, IV therapies, and longevity. They discuss what conventional medicine and health influencers often get wrong about prevention-focused care, while exploring topics like NAD+, glutathione, GLP-1s, gut health, skin aging, mitochondrial health, BPC-157, TB-500, IGF-1, and peptide safety. Dr. Ksenia also shares why testing, inflammation, absorption, and overall health matter before using peptides or other optimization treatments. Dr. Ksenia Petrushkina is a regenerative medicine practitioner based in Aventura, Florida, and part owner of Ideal Medical and Wellness. Her work focuses on hormones, peptides, IV therapies, stem cells, and longevity, with a background in biopharmaceutical science and cancer research. She brings a prevention-focused, mechanism-based perspective to patient care, especially around inflammation, gut health, metabolic function, peptide safety, and age-related optimization. Dr. Ksenia Miami Instagram https://www.instagram.com/dr.kseniamiami/](https://www.instagram.com/dr.kseniamiami/) Ideal Medical and Wellness https://idealmedwell.com/](https://idealmedwell.com/) Tadalafil / Cialis https://medlineplus.gov/druginfo/meds/a604008.html](https://medlineplus.gov/druginfo/meds/a604008.html) PT-141 / Bremelanotide [https://medlineplus.gov/druginfo/meds/a619054.html](https://medlineplus.gov/druginfo/meds/a619054.html) GHK-Cu copper peptide https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/) Tretinoin / Retin-A https://medlineplus.gov/druginfo/meds/a682437.html](https://medlineplus.gov/druginfo/meds/a682437.html) NAD+ https://pmc.ncbi.nlm.nih.gov/articles/PMC7963035/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7963035/) Nicotinamide Riboside / NR https://pmc.ncbi.nlm.nih.gov/articles/PMC6611812/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6611812/) Tru Niagen [https://www.truniagen.com/](https://www.truniagen.com/) Glutathione https://pmc.ncbi.nlm.nih.gov/articles/PMC4684116/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4684116/) GLP-1 drugs https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) Tirzepatide https://medlineplus.gov/druginfo/meds/a622044.html](https://medlineplus.gov/druginfo/meds/a622044.html) BPC-157 https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/](https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/) TB-500 / Thymosin beta-4 https://pubmed.ncbi.nlm.nih.gov/22074294/](https://pubmed.ncbi.nlm.nih.gov/22074294/) Melanotan II https://dermnetnz.org/topics/melanotan-ii](https://dermnetnz.org/topics/melanotan-ii) IGF-1 test https://medlineplus.gov/lab-tests/igf-1-insulin-like-growth-factor-1-test/](https://medlineplus.gov/lab-tests/igf-1-insulin-like-growth-factor-1-test/) Tesamorelin https://medlineplus.gov/druginfo/meds/a611035.html](https://medlineplus.gov/druginfo/meds/a611035.html)   Thymosin Alpha-1 https://pmc.ncbi.nlm.nih.gov/articles/PMC7747025/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7747025/) SS-31 / Elamipretide https://pmc.ncbi.nlm.nih.gov/articles/PMC11816484/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11816484/) Urolithin A https://pubmed.ncbi.nlm.nih.gov/35050355/](https://pubmed.ncbi.nlm.nih.gov/35050355/) Coenzyme Q10 / CoQ10 https://www.nccih.nih.gov/health/coenzyme-q10](https://www.nccih.nih.gov/health/coenzyme-q10) Pancreatic enzymes https://medlineplus.gov/druginfo/meds/a604035.html](https://medlineplus.gov/druginfo/meds/a604035.html) Psyllium husk https://medlineplus.gov/druginfo/meds/a601104.html](https://medlineplus.gov/druginfo/meds/a601104.html)   Show Notes 00:00 Welcome to the Hart2Heart Podcast 00:38 Preventive Medicine Debate 03:03 Low Dose Cialis Basics 05:03 Prostate Cancer Link 08:18 ED Alternatives PT-141 11:52 Skin Aging Essentials 12:19 GHK-Cu Dosing Risks 15:59 Copper Uglies Explained 19:47 NAD Boosting Options 24:33 NR Infusions Trend 27:38 Glutathione and Thyroid 31:58 Stopping Levothyroxine 33:34 Glutathione Precursors Limits 34:58 Gut Protocol NAD GLP1 35:59 Tirzepatide Microdosing Guide 38:18 Glutathione Injection Protocol 40:47 BPC 157 Cancer Myth 43:28 BPC TB500 Injury Cycles 45:13 Melanotan II Skin Risks 46:50 IGF1 Aging Tradeoffs 49:16 Safest GH Secretagogue 50:05 Underrated Thymosin Alpha 52:35 Mitochondria Peptides SS31 55:00 MITC and AMPK Hype 56:36 Urolithin A and CoQ10 01:00:36 GLP1 Supplements and Labs 01:02:39 Wrap Up and Where to Find   The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

Dr. Mindy talks about Crab Boils. And then she answers questions about numb tongue, why do men age so well, tennis elbow, Adderall, side effects of Semaglutide, how many grams of fiber do you need, NAD formulations, allergy headaches, blurred vision with Tirzepatide, lump on a toddler's chin, ice cold feet, another Adderall question, grey hair, tally-whackers and loud tummy noises. https://www.youtube.com/@TheDrMindyExperiment See omnystudio.com/listener for privacy information.

All links here: https://hunterwilliamshealth.com/links00:00 — Intro and why I'm doing these masterclasses02:42 — What we're covering and the regulatory timeline04:04 — The two users: weight loss vs longevity05:30 — What Retatrutide actually does (the three receptors)06:50 — Why the glucagon receptor makes Retatrutide different07:54 — Weight loss trial data (1mg to 12mg)10:50 — The longevity data: liver fat, ApoB, blood pressure13:14 — Who the lean biohacker user is13:50 — The titration playbook15:32 — Once weekly vs split dosing19:50 — Morning vs night injections21:02 — How far to push the dose (why 8mg is the ceiling)22:50 — How long to stay on and the regain problem25:44 — Longevity maintenance protocol26:34 — Lean user protocol27:24 — Protein and training are non-negotiable29:06 — Side effects and how to manage them30:20 — The heart rate question and why I use taurine32:00 — The weird skin sensitivity issue33:48 — Pairing Retatrutide with testosterone35:56 — Drug interactions (blood pressure, thyroid, insulin)37:02 — Metrics that matter38:42 — How to cycle off correctly39:54 — The most common mistakes40:42 — How to start, what to do if you plateau43:04 — Should you switch from Tirzepatide?45:28 — Combining Retatrutide with other peptides46:50 — The Ten Commandments of Retatrutide use47:50 — The bottom lineToday's episode is the first in a new format I'm rolling out. I'm working on a book where I cover one peptide at a time, one chapter at a time. Alongside that, I wanted to do a masterclass on each peptide and condense down everything I know into one place. First up is Retatrutide.I cover what it actually does in your body, the two very different users that should be on it, and the dosing strategies that get debated to death online. We go through the weight loss data, the longevity data, and why I think 8 milligrams is the real ceiling for most people. I also break down once weekly versus split dosing, the heart rate question, the skin sensitivity issue, and why testosterone optimization has to come first.If you want a definitive guide on Retatrutide, this is it. My goal is that you walk away with a framework you can actually use, whether it's on yourself, your coaching clients, or your patients.Let me know what you think. I plan on doing many more of these on every peptide that matters.⚠️ For research and entertainment purposes only. ⚠️

In this weekly roundup of news coverage, Nick breaks down important stories you might have missed that we should all have eyes on.   Retatrutide Explained: Is It Better Than Ozempic & Mounjaro? A Date Now Costs $200, AI is   Retatrutide is being called the next Ozempic — but is it actually better than Mounjaro and Tirzepatide? Dr. Jeff Gross explains how it works, fat loss results, and what people should know before using it.   Dating Now Costs $200 a Date—Here's Why Gen Z Is Giving Up   Dating now costs nearly $200 per night, and Gen Z is quitting the dating scene. Here's how inflation, dating apps, and 'dateflation' are destroying modern relationships.   Source: https://fortune.com/2026/05/05/is-dating-worth-it-anymore-average-cost-of-dating-nears-200-dollars/    AI Is Making Your Electric Bill EXPLODE (Here's Proof)   AI data centers are draining the power grid and raising electricity prices nationwide. Here's why your bill is exploding — and what we can do about it.   Source: https://chicago.suntimes.com/consumer-affairs/2026/05/13/comed-electric-customer-bills-rising-ai-data-centers-pjm-energy-costs    Our Mission Eyes Wide Open is a space for honest communication. Our goal is to remove the stigmas around mental health, holistic lifestyles, culture, and free speech so you can show up as your authentic self with your eyes wide open. By having real conversations about difficult truths, we move toward collective healing.   Timestamps 00:00 - Introduction to the Eyes Wide Open weekly round-up 01:07 - Retatrutide Explained: Is It Better Than Ozempic & Mounjaro? 13:45 - Dating Now Costs $200 a Date—Here's Why Gen Z Is Giving Up 25:38 - AI Is Making Your Electric Bill EXPLODE (Here's Proof) Find Nick Thompson here:   Nick Instagram: https://www.instagram.com/nthompson513/   UCAN Instagram: https://www.instagram.com/the_ucan_foundation/     YouTube: https://www.youtube.com/@EyesWideOpenContent      LinkedIn: https://www.linkedin.com/in/nickthompson13/       UCAN Foundation: https://theucanfoundation.org/ 

Are GLP-1 medications like Semaglutide, Tirzepatide, and Retatrutide helping or hurting your recovery? In this episode I cut through the hype and fear to talk about the real dangers people aren't discussing, how these medications should actually be used, and why no tool can replace healing your relationship with food. If you're considering a GLP or already using one, this is an important conversation you need to hear.Grab your copy of my FREE 9 page Beginner's Guide to Food Sobriety https://www.foodfreedomwithmary.com/foodsobrietyguideFood Freedom Online Course: https://www.foodfreedomwithmary.com/foodfreedomcourseFood Sobriety Mini Course -https://www.foodfreedomwithmary.com/foodsobrietymcWant to learn more about me and my coaching programs? Do you need private coaching and intensive daily contact with a coach? Fill out my application so we can chat about whether or not my program is for you and which option is best for you. Payment plans available. Don't see a payment option that works for your pay schedule? Let's chat about a custom pay plan.www.foodfreedomwithmary.com/chooseyourpath Join my online community The Food Freedom Tribe! An online community of support, eduction, inspiration, accountability….. Learn more here: https://www.foodfreedomwithmary.com/tribemembership Application: https://docs.google.com/forms/d/1upnWHYK0RXfmyRTqlsF_R06z3NA8LZYHIMWFykq7-X4/viewformInstagram: www.instagram.com/coachmaryroberts Facebook: www.Facebook.com/ketomary71 Facebook group: https://www.facebook.com/groups/4915319108493196/?ref=share_group_linkWebsite: www.foodfreedomwithmary.com Join the email list.Email: mary@foodfreedomwithmary.com

Could the "weight-loss shots" everyone is talking about actually be the next big breakthrough in cancer prevention? In this week's episode of the FMI podcast, I'm joined once again by our Chief Medical Officer, Dr. Mark Holthouse. While Dr. H is a world-renowned expert in hormone health and cardiometabolic medicine, today we are diving into a topic that is reshaping the future of longevity: the direct link between obesity-related cancers and GLP-1 medications. We recently learned that colon cancer is now the leading cause of cancer death for men and women under 50. It's a sobering statistic, but there is hope in the evolving science of metabolic medicine. In this episode, we discuss: The "Four Horsemen" of Aging: Why cardiovascular disease, cancer, dementia, and insulin resistance are all driven by the same cellular pathways. GLP-1s Beyond Weight Loss: How medications like Semaglutide and Tirzepatide work at the cellular level to potentially reduce tumor volume and progression. The "New Kid on the Block": A deep dive into Retatrutide, the experimental triple-agonist showing even more dramatic results in preclinical models. Obesity-Related Cancers: Why fatty liver, chronic inflammation, and nutrient-sensing pathways (like mTOR) create a "pro-cancer milieu." The "Foundational Four": Why, despite all the medical breakthroughs, sleep, clean eating, stress management, and exercise remain the ultimate levers for health. Dr. Holthouse also shares his "minimalist" approach to detoxification and why he's more interested in "reining patients in" from expensive gadgets to focus on what actually moves the needle. Whether you are interested in the latest longevity science or simply looking for ways to lower your family's risk of chronic disease, this conversation is packed with "root cause" insights you won't want to miss.

Joanne Alves e Nordman Wall convidam Caroline Millon para discutir a abordagem da Síndrome de Apneia e Hipopneia Obstrutiva do Sono (SAHOS). Referências: Myers, Kathryn A et al. “Does this patient have obstructive sleep apnea?: The Rational Clinical Examination systematic review.” JAMA vol. 310,7 (2013): 731-41. doi:10.1001/jama.2013.276185Gawrys, Breanna et al. “Obstructive Sleep Apnea in Adults: Common Questions and Answers.” American family physician vol. 110,1 (2024): 27-36.Hong, Yanan et al. “The study of the relationship between moderate to severe sleep obstructive apnea and cognitive impairment, anxiety, and depression.” Frontiers in neurology vol. 15 1363005. 10 May. 2024, doi:10.3389/fneur.2024.1363005US Preventive Services Task Force et al. “Screening for Obstructive Sleep Apnea in Adults: US Preventive Services Task Force Recommendation Statement.” JAMA vol. 328,19 (2022): 1945-1950. doi:10.1001/jama.2022.20304Palombini, Luciana de Oliveira. “Critérios diagnósticos e tratamento dos distúrbios respiratórios do sono: RERA” [Diagnostic criteria and treatment for sleep-disordered breathing: RERA]. Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia vol. 36 Suppl 2 (2010): 19-22. doi:10.1590/s1806-37132010001400007Yeghiazarians, Yerem et al. “Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association.” Circulationvol. 144,3 (2021): e56-e67. doi:10.1161/CIR.0000000000000988Duarte, Ricardo Lm et al. “Obstructive Sleep Apnea Screening with a 4-Item Instrument, Named GOAL Questionnaire: Development, Validation and Comparative Study with No-Apnea, STOP-Bang, and NoSAS.” Nature and science of sleep vol. 12 57-67. 23 Jan. 2020, doi:10.2147/NSS.S238255Gottlieb, Daniel J, and Naresh M Punjabi. “Diagnosis and Management of Obstructive Sleep Apnea: A Review.” JAMA vol. 323,14 (2020): 1389-1400. doi:10.1001/jama.2020.3514Malhotra, Atul et al. “Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.” The New England journal of medicine vol. 391,13 (2024): 1193-1205. doi:10.1056/NEJMoa2404881

In this episode, we rank the first 10 healthiest snacks for fat loss from S (supreme) to F-tier.We hope you enjoy this episode and if you'd like to join us in The Online Fitness Business Mentorship, you can grab your seat at https://www.fitnessbusinessmentorship.comThank you!-J & MWATCH this episode on YouTube: https://youtu.be/vDusakRLsasTIMESTAMPS:(00:00) — Intro(00:11) — This is your LAST CHANCE to get into the Mentorship at the lowest price it will EVER be (don't say we haven't warned you)(01:14) — So... Jordan probably has 2 dogs now?(04:05) — Mike's current training and the difference between being driven by the light rather than the darkness(07:24) — Confirmed: social media still sucks(10:13) — Tirzepatide, Retatrutide, and the fear of missing out(14:22) — Ranking the top 20 healthiest snacks for fat loss (S to F tier)(46:37) — Thanks for listening! (this is your LAST CALL to get into the Mentorship before prices increase!)You can find a full transcript of this episode by clicking hereFollow the show on social:YouTube - https://www.youtube.com/@personaltrainerpodcastInstagram - https://www.instagram.com/personaltrainerpodcastTikTok - https://www.tiktok.com/@personaltrainerpodcastJoin our email list & get our FREE '30 Ways To Build A Successful Online Coaching Business' manual: https://bit.ly/30O2l6pCheck out our book 'Eat It!' at https://www.amazon.com/Eat-It/dp/0008543046If you have any questions you'd like to have answered on the show, shoot us an email at info@fitnessbusinessmentorship.comIf you enjoyed the episode, we would sincerely appreciate it if you left a five-star review.----Post-Production by: David Margittai | In Post MediaWebsite: https://www.inpostmedia.comEmail: david@inpostmedia.com© 2026 Michael Vacanti & Jordan Syatt

Could GLP-1 medications be the missing piece in treating inflammatory skin disease? In this episode of Science is Skin, Dr. Ted Lain sits down with Dr. Lindsey Bordone — former Columbia University associate professor of dermatology, now in private practice at Bordone Dermatology in Scottsdale, Arizona — for a deep dive into metabolic disease and the skin. Dr. Bordone was among the first dermatologists to prescribe GLP-1 agonists for her patients, and in this conversation she explains exactly why. From the link between hyperinsulinemia and chronic inflammation to the visible skin signs of insulin resistance — skin tags, acanthosis nigricans, forearm hair loss — she makes the case that dermatologists are uniquely positioned to catch metabolic disease before any other specialty. Dr. Bordone walks through how she uses tirzepatide (Mounjaro/Zepbound), semaglutide (Ozempic/Wegovy), and the emerging triple-G drug retatrutide, including her lab protocols, dosing philosophy, how to manage GI side effects, and the surprising interaction between GLP-1s and estrogen therapy. In this episode: Why high BMI reduces biologic efficacy in psoriasis patients How to check fasting insulin (HOMA-IR) and why most physicians aren't doing it Skin signs of insulin resistance: skin tags, forearm hair loss, and neck skin thickening Tirzepatide vs. semaglutide vs. retatrutide — how to choose and when Retatrutide's remarkable 93% fatty liver clearance rate in clinical trials The truth about sarcopenia and muscle loss on GLP-1 medications Dosing protocols, side effect management, and when NOT to escalate quickly Protein intake recommendations during active weight loss Estrogen and GLP-1 synergy — what dermatologists need to know Lab work to run before and during GLP-1 therapy How to build an insurance case for continued medication coverage Resources mentioned: HOMA-IR fasting insulin/glucose testing AAD resources on metabolic dermatology Bordone Dermatology — Scottsdale, Arizona Enjoyed this episode? Share it with a colleague and leave us a five-star review. Subscribe so you never miss an episode of Science is Skin. To watch this and other episodes, be sure to check out our YouTube page DISCLAIMER: This podcast is not intended to provide diagnosis, treatment, or medical advice. Content provided in this podcast is for educational purposes only. Please consult with a physician regarding any health-related diagnosis or treatment.See omnystudio.com/listener for privacy information.

Jordan and Nate finally tackle the buzzword everyone's been throwing around: peptides. From Ozempic and Gila monster spit to copper creams and hairy butt cheeks (yes, really), the guys break down what peptides actually are, why they suddenly went viral, and whether the hype is justified. They cover the basics in plain English with a fun letters-words-sentences analogy, dig into RFK Jr.'s deregulation of compounding pharmacy peptides, and walk through the most popular ones on the market today. BPC-157 for injury repair, GHK-Cu for skin and hair, Semax for cognition, Melanotan for tanning, Tesamorelin, Tirzepatide, MOTS-c, PT-141, and a few that had the guys laughing about where exactly you're supposed to inject them. Along the way, they discuss peptides hiding in your food (eggs, bone broth, sauerkraut, mushrooms), why aspartame is technically a peptide too, and the difference between supporting your body's natural processes versus messing with gene therapy. As always, the message is the same: tools are tools. Don't reach for the magic injection when whole food and a real lifestyle would do the trick.

Episode 217: Automate Your Lead Generation with our FREE online course: https://go.digitaltrailblazer.com/auto-leads-course-freeMany online business owners eventually hit a wall - whether it's a profit ceiling, misalignment with their audience, or a business model that no longer feels right. Staying stuck in the wrong direction doesn't just kill momentum, it drains your energy and keeps you from building something that truly works.In this episode, Horace Dobson teaches us how to make smart decisions around rebranding and pivoting your business, including how to identify whether you're facing a real alignment problem or just a marketing fix, why finding a unique position in your market eliminates the need to compete on price, and why investing in the right mentorship is the fastest path to breakthrough results.About Horace Dobson: Horace is a registered nurse, disabled U.S. veteran, entrepreneur, and multi-genre author whose life reflects a true rags-to-riches transformation. After nearly 30 years working on hospital floors across the United States, he stepped away from traditional healthcare to found Warrior Weightloss and create Empowered AI - a consumer-focused health-intelligence platform helping people take control of their metabolism, mindset, and longevity through real-world data and accountability, not hype.Beyond business, Horace is deeply committed to service, supporting disabled veterans, foster parents, and families facing food insecurity throughout West Palm Beach County. He is also the author of multiple books spanning health, mindset, and personal transformation — including The Comeback, available free in audiobook form by searching "Horace Dobson The Comeback."Visit Warrior Weightloss here: https://www.warriorweightloss.com/Mention the Digital Trailblazer podcast for 20% off any Weight Loss medications, such as Semaglutide or Tirzepatide at https://www.360lifeshift.comConnect with Horace: Facebook - https://www.facebook.com/profile.php?id=61575535337510 YouTube - https://youtube.com/@evolifewellness?si=aj_CQ0HPM02XppAT LinkedIn - https://www.linkedin.com/in/horace-dobson-ba82a23a/ Instagram - https://www.instagram.com/theempowered.ai/Want to SCALE your online business bigger and faster without the endless hustle of networking, referrals, and pumping out content that nobody sees?Grab our Ultimate Ad Script for Coaches, Agencies, and Course Creators.Learn the exact 5-step script we teach our clients that allows them to generate targeted, high-quality leads at ultra-low cost, so you can land paying customers and clients without breaking the bank on ad spend.Grab the Ultimate Ad Script right HERE - https://join.digitaltrailblazer.com/ultimate-ad-script✅ Connect With Us:Website - https://DigitalTrailblazer.comFacebook - https://www.facebook.com/digitaltrailblazerTikTok: https://www.tiktok.com/@digitaltrailblazerX (Twitter): https://x.com/DgtlTrailblazerInstagram: https://www.instagram.com/DigitalTrailblazer

GLP-1 drugs like Ozempic and Mounjaro are now everywhere. But what do they actually do beyond weight loss? And what do you need to know before starting them? In this episode, we're joined by Dr Ania Jastreboff, a world-leading researcher at the forefront of GLP-1 treatments and writer of the New York Times bestselling book Enough: Your Health, Your Weight, and What It's Like To Be Free, co-authored with Oprah Winfrey. Dr Jastreboff explains everything you need to know about Ozempic, Mounjaro, Wegovy and other GLP-1 medications for 2026. You'll learn how GLP-1s may reduce the risk of heart disease, improve blood sugar control, and support conditions like sleep apnoea. We also explore why weight often returns after stopping, and what you need to know about Ozempic side effects and long-term use. If these drugs can change how your brain controls hunger, what does that mean for willpower, weight gain, and how we treat obesity long term?

Three years ago, GLP-1 peptides were barely being talked about in the midlife women's health space. Since then, Jessica and I have personally used them, experimented with different approaches, and helped over a thousand women inside our peptide program navigate what works, what backfires, and what women in perimenopause and menopause need to know before jumping in. In this episode, we're pulling back the curtain on our own GLP-1 journeys, including my rough start with Ozempic, why Tirzepatide worked better for me, Jessica's experience with Semaglutide and fatigue, and why Retatrutide is becoming one of the most talked-about peptides right now. We also get into one of the biggest myths floating around online: that GLP-1s automatically cause massive muscle loss. The truth is much more nuanced. We talk about the biggest mistakes we see women making. How Glp1s can impact insulin sensitivity, inflammation, fat cell biology, blood sugar regulation, liver metabolism, and even brain reward pathways. We also dive into some of the peptides we're loving right now beyond GLP-1s, including NAD, KPV, MOTS-c, and Tesamorelin, and why peptide therapy can be powerful when it's used intelligently, not recklessly. This is a real, honest conversation about how to use these tools in a way that supports long-term health, metabolism, muscle, and hormones, instead of chasing fast weight loss at any cost. In this episode, we cover: Our personal three-year journey using GLP-1 peptides Why Ozempic, Semaglutide, Tirzepatide, and Retatrutide can feel very different The truth about GLP-1s and muscle loss Why appetite suppression is not the only sign a GLP-1 is working The biggest mistakes women make with dosing and titration Why protein, amino acids, digestion, and strength training matter so much How GLP-1s may support insulin sensitivity, inflammation, blood sugar, and metabolic health Why some women don't lose weight until thyroid, hormones, food sensitivities, or inflammation are addressed What we're seeing with Retatrutide and why it's getting so much attention Peptides beyond GLP-1s, including NAD, KPV, MOTS-c, and Tesamorelin Who This Episode Is For This episode is for women in perimenopause or menopause who are using GLP-1s, thinking about starting them, or wondering why they are not getting the results they expected. It is especially helpful if you are worried about muscle loss, hair shedding, fatigue, dosing, long-term use, maintenance, or whether peptides are actually supporting your metabolism or just helping you eat less.     Sponsors Join our FREE upcoming masterclass: Why Midlife Weight Gain Won't Budge A smarter way to use GLP-1s in midlife without wrecking muscle or metabolism When: April 30th 11 am PST Register here: https://coaching.karenmartel.com/glp1-masterclass    Add MitoQ Hormonal Metabolic Support to your midlife support toolbox: www.mitoq.com/karenmartel get 10% off your order with code: MARTEL10     Are you in perimenopause or postmenopause and struggling with symptoms—but not getting the support you deserve? At Midlife Solutions, we specialize in hormone optimization for women in midlife. Our all-female clinical team offers telehealth care across all 50 U.S. states, with the ability to prescribe bioidentical estrogen, progesterone, testosterone, and thyroid medication.   Book your FREE Hormone Discovery Call Find out what's really driving your symptoms and what your next best steps are.   Visit the website: https://karenmartel.com   Shop the Midlife Solutions Store Over-the-counter bioidentical hormone creams and oils — no prescription needed. Including: • Progesterone • Estrogen Face Cream • Vaginal Moisturizer and more!   Take the Hormone Quiz Discover hidden hormone imbalances that could be driving your symptoms. Get personalized results (and yes, they may surprise you).   Women's Peptide Weight Loss Program Clinically guided, hormone-aware weight loss for midlife women.   Midlife RESET HRT Program A complete, supportive approach to hormone replacement therapy in midlife.   Your host: Karen Martel Certified Hormone Specialist, Transformational Nutrition Coach, & Weight Loss Expert   Karen's Facebook Karen's Instagram

Most disciplined executives and entrepreneurs aren't struggling with fat loss because of effort or willpower. They're struggling because they're out of sequence—jumping straight to peptides, compounds, and advanced protocols before the three biological levers that actually drive fat loss are even stable.In this episode, Julian Hayes II breaks down the exact three mechanisms that determine whether your body gets lean and stays lean—and how to pull each one in the right direction before layering in anything advanced.You'll walk away understanding why fat loss is a sequencing problem, not a knowledge problem, and what it actually looks like to build a metabolic foundation that performs the way your business does. For executives and entrepreneurs operating in high-stakes environments, this episode connects biology directly to business performance.— Episode Chapter Big Ideas (timing may not be exact) —0:00 – Why disciplined high performers still don't look the part 1:57 – The three biological levers behind sustainable fat loss2:51 – About Julian and Executive Health3:26 – Who this conversation is actually for 4:49 – Lever 1: Nutrient Partitioning: where do your calories actually go?6:04 – The capital allocation analogy: investing in lean tissue vs. storing fat6:50 – The four factors that determine partitioning efficiency12:26 – Practical foundation: how to optimize partitioning before going advanced13:19 – Earning your carbs: the Charles Poliquin philosophy15:30 – GLP-1 receptor agonists and nutrient partitioning15:49 – Testosterone and hormonal optimization: Why hormones make everything go18:06 – Lever 2: Recovery Signaling: Where most high performers self-sabotage19:09 – What recovery signaling actually controls in a deficit19:33 – Cortisol21:02 – Growth hormone22:07 – Thyroid conversion: the T4 to T3 problem nobody talks about24:15 – HRV: your autonomic nervous system's engine light27:07 – Practical recovery: sleep timing and maximizing slow-wave GH pulses28:53 – Protein in a deficit: the primary defense against muscle loss29:39 – Electrolytes, magnesium, and why micronutrients matter more on GLPs32:51 – Advanced layer: CJC-1295 and Ipamorelin34:17 – Exogenous HGH: beyond bodybuilding34:54 – BPC-157 and TB-500: the gateway peptides for recovery35:58 – The 90/95 rule: foundation is the work, advanced tools are the amplifier36:34 – Lever 3: Appetite and Energy Regulation: the compliance lever37:22 – Why fat loss is a compliance problem, not a knowledge problem37:34 – Food noise is biological, not psychological38:51 – What poor appetite regulation actually costs executives40:24 – How aggressive deficits suppress testosterone41:15 – Performance as the feedback loop for energy regulation43:00 – Fiber, gut health, and natural GLP-1 secretion44:06 – Meal timing and circadian biology46:52 – Advanced layer: Semaglutide, Tirzepatide, and Retatrutide explained50:30 – Muscle loss, GI risk, and why lifestyle habits are the real variable51:24 – Genetics and fat loss52:47 – Low-dose Naltrexone54:19 – Thymosin Alpha-1 and emerging peptide research on energy regulation55:36 – Tying it all together: Foundation First, Amplification Second57:01 – The cost of skipping a sequence59:05 – The executive case for fat loss beyond aesthetics1:01:30 – How to work with Julian privately— Connect with Julian and Executive Health —LinkedIn — https://www.linkedin.com/in/julianhayesii/X — https://x.com/thejulianhayesReady to take your health, leadership, and performance to the next level? Book an exploratory call —https://www.executivehealth.io/contactWebsite — https://www.executivehealth.io/***DISCLAIMER: The information shared is not meant to treat or diagnose any condition. This is for educational, informational, and entertainment purposes. The content here is not intended to replace your relationship with your doctor and/or medical practitioner. Consult your provider before making any decisions.

Major disruption hits the GLP-1 landscape as another large 503B compounding pharmacy halts production of semaglutide and tirzepatide. In this episode, we unpack what's driving the FDA's increased enforcement and why these shutdowns could signal a broader shift in the compounded medication market.Joined by Sabina Hemmi from glpwinner.com, we break down the key differences between 503A and 503B pharmacies, what these changes mean for supply and patient access, and why delays in prescriptions may be on the horizon. We also dive into the growing legal battles between pharma companies and telehealth providers and what that could mean for the future of affordable GLP-1 options.If you're using or considering compounded GLP-1s, this episode covers what you need to know right now and what could be coming next.

Microdosing GLP-1 agonists can create powerful shifts in your body—when they're used the right way. The problem? Most people (and even many doctors) are using them as a quick-fix weight loss tool. And when that's the approach, of course you see burnout, terrible side effects, and rebound weight gain. But that doesn't mean these compounds are the problem. It means the strategy is. When used in a microdosing approach, GLP-1 agonists can support your body on a much deeper level—helping improve insulin sensitivity, reduce inflammation, and calm an overworked nervous system. Especially if your body has been stuck in chronic stress or survival mode, this can be the missing piece that allows your system to finally feel safe enough to function differently. This isn't about forcing weight loss. It's about creating the internal environment where your body can release it. You don't have to stay on these forever. You don't have to suffer through harsh side effects. But you do need a more intentional, supportive approach. In this episode, I'll show you what that actually looks like. When you're ready to release the extra weight for good—and finally support your nervous system, metabolism, and relationship with food—it's time to have a conversation. Schedule your free consultation to explore what working together could look like, and whether my 3-part process is the right fit for you. www.bodyyoucrave.com/schedule  Chapters (00:00:02) - Hungry for Love(00:00:26) - Gaining Weight With GLP1s(00:06:21) - Turning off your brain: The process(00:06:56) - Tirzepatide and Semaglutide:(00:12:39) - Microdose for Perimenopausal and Menopausal Women in Their 60(00:21:04) - How to Lose Weight With a Strategic Approach(00:22:06) - Pregnant women on GLP1s(00:29:58) - How to manage emotional eating with GLP1(00:33:17) - How to Break the Cycle Around Binge Eating

When Penn Holderness described APOE4 as a “ticking time bomb,” it struck a nerve for a lot of people, especially women in midlife who already feel vulnerable about their brain health.Could a GLP-1 medication protect your brain if you carry the APOE4 gene? Amy unpacks the science in plain English and explains why genes are not destiny, why menopause changes the conversation for women, and what research-backed actions you can start taking right now.What to Listen For[00:00] Why Penn Holderness's APOE4 reveal sparked such a big reaction [02:30] What it actually means to carry one or two copies of the APOE4 gene [05:30] Why APOE4 is a genetic predisposition, not a verdict [08:30] The critical difference between APOE4 and the rare genes that directly cause early-onset Alzheimer's [10:30] Why midlife and postmenopausal women may face a different level of APOE4-related risk [14:00] How fear drives people toward quick-fix solutions and why that matters in Alzheimer's prevention [18:00] What the observational GLP-1 research shows and the big caveat most people miss [22:00] What the EVOKE and EVOKE Plus semaglutide trials found in people with early Alzheimer's symptoms [25:30] What hormone therapy can do for sleep and symptom relief — and what it has not been proven to do for dementia prevention [28:30] Why the FINGER study, U.S. POINTER, and modifiable risk-factor research offer the most hopeful path forward [32:30] The free RESTORED guide, the 8 evidence-based lifestyle factors, and Amy's call to take action without panicIf you've been feeling afraid of your genetic risk, this episode is your reminder that APOE4 is not destiny. Amy explains why the most powerful path forward is still grounded in the basics: sleep, movement, metabolic health, stress management, and consistent daily choices. Listen now, subscribe to the show, and grab Amy's free guide so you can start protecting your brain one step at a time.From The EpisodeDownload the free RESTORED ProtocolBook your Breakthrough Roadmap sessionResearch cited in this episode:1. NIA Alzheimer's Disease Genetics Fact Sheet — APOE4 prevalence and risk breakdown https://www.nia.nih.gov/health/alzheimers-causes-and-risk-factors/alzheimers-disease-genetics-fact-sheet2. Altmann A et al. (2014). Sex modifies the APOE-related risk of developing Alzheimer disease. Annals of Neurology. https://pmc.ncbi.nlm.nih.gov/articles/PMC4117990/3. Stanford Medicine (April 2026). Women get Alzheimer's more often than men: Five things the science tells us. https://med.stanford.edu/news/insights/2026/04/women-alzheimers.html4. Alzheimer's Association (2025). Statement on oral semaglutide phase 3 topline data (EVOKE/EVOKE+ trials). https://www.alz.org/news/2025/alzheimers-assRESOURCES:Book a FREE Discovery Call with AmyOrder Amy's book Thoughts Are Habits Too:  Master Your Triggers, Free Yourself From Diet Culture, and Rediscover Joyful Eating.Schedule your Breakthrough Roadmap session with AmyFollow Amy on Instagram @amylangcoaching Follow Amy on Facebook @amylangcoachingSubscribe to Amy's YouTube channel @happyandhealthywithamy

In this episode, we discuss the most important annual updates in the American Diabetes Association Guidelines, Standards of Care 2026, particularly focusing on changes in pharmacotherapy recommendations and the supporting evidence. Key Concepts A few existing agents now have ASCVD risk reduction data in patients with existing ASCVD or high indicators for ASCVD. They are: oral semaglutide and tirzepatide.  SGLT2is are still first-line in patients with diabetes and HF including HFpEF, but SC semaglutide and tirzepatide are now recommended for those with symptomatic HFpEF and obesity due to positive outcomes in this population. The GLP-1RA and dual GLP-1/GIP RA are the preferred agents for weight management in patients with T2DM, but use of GLP-1RA can be considered for weight loss in patients with T1DM. The guideline also better defines recommendations for medication-induced hyperglycemia from immune checkpoint inhibitors, PI3Kɑ (phosphoinositidylinositol 3-kinase α) inhibitors, mTOR inhibitors, and steroids.  References American Diabetes Association. Standards of care in diabetes—2026. Diabetes Care. 2026;49(suppl 1):S1-S377. SOUL study. Darren K. McGuire, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392(20):2001-2012. doi:10.1056/NEJMoa2501006. SURPASS-CVOT. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025;393(24):2409-2420. doi:10.1056/NEJMoa2505928. SUMMIT. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427-437. doi:10.1056/NEJMoa2410027. STEP-HFpEF. Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963. STEP-HFpEF DM. Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity‑related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394‑1407. doi:10.1056/NEJMoa2313917.

Send us Fan Mail We finally made it to Dallas, and let's just say the Big D stood for more than just the city name. In this episode, we're peeling back the foil on our own incompetence—specifically how we've been winging our medical prescriptions while trying to maintain a 10/10 aesthetic. We're diving into the "Modern Grime" of our travel habits, from the "Cornhole Lesbians" of Texas to the absolute panic of a self-driving car that almost ended it all before we even reached the hotel. It's honest, it's messy, and it's the definitive proof that we are "Not Well." The Top 10 Chaotic TakeawaysThe Dosage Disaster: Realizing you've been taking a fraction of the intended dose for months while wondering why you hit a weight loss plateau.Dallas vs. The World: Surviving a trip to Texas that included questionable navigation and even more questionable life choices.The Self-Driving Death Trap: A harrowing encounter with a Tesla that decided a 90-degree horizontal turn in construction was "the vibe."Cornhole Lesbians: Being validated by the most unexpected demographic in a Dallas bar and immediately feeling "pretty."The "Hotspot" Shower: Redefining hygiene as a tactical strike on specific body parts when time (and energy) is running low.Medical Non-Compliance as Art: Treating prescription instructions like the "Terms and Conditions" page—just scrolling to the bottom and clicking "agree."The 3 AM Alfredo Pipeline: The inevitable journey from a night out to a bowl of pasta that you definitely didn't need but absolutely deserved.Lanyard Loathing: A deep-seated hatred for conference lanyards and the "dorky" energy they bring to an otherwise high-fashion aesthetic.The Korean Spa Revelation: Navigating the vulnerability of a spa day while trying to maintain the "Hot but Chaotic" hierarchy.Rebranding the Mess: Launching a new, professional logo while simultaneously admitting your life is currently a beautiful, grainy, indie-film disaster.Support the showAs always you can write us at nowellpodcast@gmail.com or call us at ‪(614) 721-5336‬ and tell us your Not Wells of the week InstagramTwitterBobby's Only FansHelp us continue to grow and create amazing content, like a live tour or just help fund some new headphones when needed. Any help is appreacited. https://www.buzzsprout.com/510487/subscribe#gaypodcast #podcast #gay #lgbtq #queerpodcast #lgbt #lgbtpodcast #lgbtqpodcast #gaypodcaster #queer#instagay #podcasts  #podcasting #gaylife  #pride #lesbian #bhfyp #gaycomedy #comedypodcast #comedy #nyc #614 #shesnotdoingsowell #wiltonmanor #notwell

The State of Hormone & Peptide Industry with Phil Vela Disrupting the health & wellness industry. (2:15) "It's that hard to do IT, so it's that easy to succeed once you've done IT." (2:48) What he did before he started Vita Bella, and the origins of the company. (5:00) The most applicable skills gained from his previous career. (7:41) Calling out the 'Grey Market' and its competition. (9:44) The state of the peptide industry and the fallout with Transcend. (15:54) Results & service. (25:23) Breaking down the Vita Bella membership package. (30:07) Businessman at heart. (33:34) Why he believes it should be illegal to prescribe GLP-1s by themselves. (35:13) Bad actors giving bad guidance. (43:33) His outlook for the future of the industry. (45:14) Will Ozempic and Tirzepatide ultimately bankrupt the United States? (53:27) The importance and value of having a trainer while on a GLP-1. (56:47) "I didn't build this business for money. I built it for a legacy!" (59:07) "Newer" peptides that have been impressed by. (1:03:16) Rapid fire: The best peptide for… (1:11:56) Related Links/Products Mentioned Visit Vita Bella for an exclusive offer for Mind Pump listeners! ** The first 50 signups will get a Vita Bella welcome box. You can finally achieve a top 1% all-around health at an affordable price! ** Get 20% off Kion at getkion.com/mindpump ** No code needed automatically applied at check out! ** MAPS Great 8 Launch - (Retail $127, Code: LAUNCH for 50% off!) ** Launch bonus include: MAPS GREAT 8 Nutrition Guide. ** Visit: http://mapsgreat8.com/  Mind Pump Store Mind Pump Hormones Facebook Private Forum GLP-1 Litigation: Compounder Sues Eli Lilly, Novo Nordisk Mind Pump #2597: Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! Federal Court Tosses Lilly's Suit Against Strive Pharmacy: Jurisdiction Still Matters Mind Pump #2125: Heal Like Wolverine: BPC 157 with Dr. William Seeds Mind Pump Podcast – YouTube Mind Pump Free Resources Featured Guest/People Mentioned Phil Vella – "Philly" (@phillyvz) Instagram Jay Campbell (@jaycampbell333) Instagram Rick Niemi (@gods.economy) Instagram Dr. William Seeds (@williamseedsmd) Instagram Peter Attia, M.D. (@peterattiamd) Instagram